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OBJECTIVE: Our objectives were to study the relationships between 25-hydroxyvitamin D 
(25(OH)D) and preeclampsia risk, maternal genetic variation in 3 vitamin D metabolism genes 
(GC, CYP27B1, VDR) and preeclampsia risk, and variation in the same genes and 25(OH)D. 
METHODS: We used two racially diverse pregnancy cohorts (EVITA and Collaborative 
Perinatal Project (CPP)) to achieve these objectives. We estimated the association between log-
transformed 25(OH)D and preeclampsia risk in EVITA by using log-binomial regression with 
restricted cubic splines. In EVITA and CPP, we used multivariable logistic and linear regression 
models to estimate the associations between allelic variation and preeclampsia risk, and genotype 
and log-transformed 25(OH)D, respectively. Meta-analyses were conducted to calculate 
estimates of association between and within cohorts. RESULTS: Dose-response associations of 
25(OH)D were observed for both severe and mild preeclampsia. Trends of associations were 
observed in genetic variation and preeclampsia risk. Compared with major allele carriers, Black 
mothers in EVITA who carried the minor allele for rs11732451 GC single nucleotide 
polymorphism (SNP) and 2 VDR SNPs (rs4340112, rs10459217) had increased odds of 
preeclampsia, while the odds were lowered for those who carried the minor allele for 1 GC SNP 
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(rs1099028) and 2 VDR SNPs(rs757344, rs12721364). In the meta-analysis, two VDR SNPs 
(rs886441 and rs2853561) had trends of decreased odds of preeclampsia for all Black mothers. 
For the 25(OH)D analysis, statistically significant associations were observed. Compared with 
those with major allele genotypes, mothers with minor allele genotypes of rs1844885 (GC) and 
rs11168275 (VDR) had increased 25(OH)D and of rs11732451 (GC) had lowered 25(OH)D. In 
the meta-analysis on all Black mothers, rs1844885 (GC) was associated with increased 25(OH)D 
while there was a trend of decreased 25(OH)D for rs10877016 (CYP27B1). CONCLUSIONS: 
Low 25(OH)D may be enough to reduce risk of preeclampsia. If our findings are confirmed in a 
replication study, genetic variation may be an independent risk factor for maternal 25(OH)D, 
making the findings of this research relevant to public health.  
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Vitamin D deficiency is a major public health concern due to its widespread prevalence 
and its association with several diseases, including osteoporosis, osteopenia, cancer, heart 
disease, and multiple sclerosis[1-11]. The role of vitamin D in optimal pregnancy outcomes is 
contentious. Important traditional and non-traditional roles of vitamin D in pregnancy may 
include skeletal mineralization, cell differentiation and proliferation, hormone regulation, and 
regulation of inflammation[12]. Although several observational studies have reported vitamin D 
deficient women are at increased risk of preeclampsia compared with sufficient women, the 
associations have been inconsistent [13-25]. 
The discrepancy may be explained by the presence of common genetic variations in 
vitamin D metabolizing genes like GC, CYP27B1 and vitamin D receptor (VDR) genes. 
Encoding the vitamin D binding protein (DBP), the GC gene is important for modulating the 
bioavailability of vitamin D metabolites, as well as transporting vitamin D and its metabolites in 
serum[26]. These metabolites include 25(OH)D which needs to be hydroxylated by an enzyme 
encoded by CYP27B1 to become the active form of vitamin D (1,25(OH)2D or 1,25-
dihydroxyvitamin D) [27]. 1,25(OH)2D can influence biological mechanisms by binding to VDR, 
triggering a genomic response [28]. The activated VDR is involved in several biological roles in 
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pregnancy, such as placental hormone regulation and prevention of inflammation[29]. These 
roles may be disrupted in mothers with allelic variations of the GC, CYP27B1, and VDR genes, 
increasing their risk of vitamin D deficiency or adverse pregnancy outcomes like 
preeclampsia[29]. Past studies have reported common polymorphisms in the GC, CYP27B1, and 
VDR genes are associated with vitamin D deficiency and adverse health outcomes in non-
pregnant adults [30-35]. However, there is limited research on the effects of these variants on 
poor pregnancy outcomes.  
1.1  RESEARCH AIMS 
We have the unique opportunity to use existing data and banked samples to determine if 
polymorphisms in GC, CYP27B1 and VDR genes are associated with preeclampsia or vitamin D 
deficiency in pregnancy. We will use two multi-center cohorts to achieve our goal. The 
Collaborative Perinatal Project (CPP) (1959-1966) is the largest pregnancy cohort study in the 
U.S. (n=717 cases of preeclampsia). Maternal blood samples at ≤26 weeks of gestation have 
been assayed for 25-hydroxyvitamin D (25(OH)D), the indicator of vitamin D nutritional status. 
EVITA (1999-2010) is a retrospective cohort of mothers who received prenatal genetic screening 
at Magee-Womens Hospital in Pittsburgh, PA (n= 650 cases of preeclampsia). Maternal samples 
were assayed for 25(OH)D at ≤20 weeks. We will use 2514 and 2357 DNA samples from 
EVITA and CPP cohorts, respectively. The common haplotypes of these genes will be tagged to 
avoid redundancy in the genotyping of samples. Our specific aims are the following: 
Aim 1: To determine the effect of vitamin D deficiency on risk of preeclampsia. 
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Hypothesis 1: Women with vitamin D deficiency will have increased risk of preeclampsia 
compared with women with vitamin D sufficiency. 
Aim 2: To determine the relationship between maternal genetic variation in GC, CYP27B1, and 
VDR on risk of preeclampsia. 
Hypothesis 2: Risk variant carriers will have an increased susceptibility to preeclampsia.  
Aim 3: To determine the effect of GC, CYP27B1, and VDR gene on vitamin D deficiency. 
Hypothesis 3: Carriers of risk variants will have increased risk of vitamin D deficiency.  
Overall impact: Estimating associations between variation in the GC, CYP27B1, and 
VDR genes, vitamin D status, and preeclampsia may help to improve our understanding of the 
inconsistencies in past vitamin D research. Therefore, this study can make a significant impact 
on a major public health problem. 
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2. LITERATURE REVIEW 
INTRODUCTION 
The high prevalence of maternal vitamin D deficiency may be one factor contributing to adverse 
pregnancy outcomes [36, 37]. Experimental and observational studies show vitamin D 
metabolites have important roles in pregnancy, including regulating the transcription and 
function of genes associated with placental invasion and angiogenesis, modulating immune 
function and inflammatory response, as well as regulating blood pressure [38-40]. Any or all of 
these mechanisms  can potentially increase risk of preeclampsia [41]. Several observational 
studies have noted vitamin D deficient women have an increased risk of preeclampsia compared 
with sufficient women; however the associations remain equivocal [13-25]. Associations 
between genetic variations and preeclampsia risk may help explain the inconsistencies in 
observational studies. To date, only one published study has researched the effect of vitamin D 
metabolizing genetic variants on 25(OH)D levels in pregnancy [42] and preeclampsia risk [43]. 
We will investigate 371 SNPs in three metabolizing genes that either synthesize (CYP27B1), 
carry (GC), or mediate downstream signaling (VDR) by serum 25(OH)D, and the association of 
these SNPs with preeclampsia and vitamin D deficiency risks. Our goal is to determine whether 
low 25(OH)D is associated with risk of preeclampsia, and if there are risk alleles in three vitamin 
2.0
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D candidate genes. We will use samples and data from two large pregnancy cohort studies to 
address this gap in knowledge. 
VITAMIN D 
2.1.1 Metabolism 
Vitamin D, a fat-soluble pro-hormone, originates in two forms: vitamin D2 
(ergocalciferol) and vitamin D3 (cholecalciferol). Vitamin D2 is found naturally in food like oily 
fish, plants, and vegetables, while vitamin D3 is found in fortified foods, such as dairy products, 
and dietary supplements [44-48]. Most vitamin D3 synthesis occurs in the skin when UVB light 
is absorbed and interacts with 7-dehydrocholesterol. After skin synthesis and food absorption, 
vitamin D2 and D3  in serum are transported to the liver for hydroxylating reactions by 
chylomicrons and the vitamin D binding protein (DBP, encoded by GC gene) [29, 48, 49]. 
Once vitamin D2 and D3 enter the liver, enzyme-driven hydroxylating reactions convert 
the prohormones to 25(OH)D (25-hydroxyvitamin D or calcidiol). An enzyme called 25-
hydroxylase mediates these reactions, which is an enzyme encoded by either CYP2R1 or 
CYP27A1 (cytochrome P450, family 2, subfamily R, polypeptide 1; cytochrome P450, family 27, 
subfamily A, polypeptide 1) [29]. Circulating 25(OH)D is the best marker for vitamin D 
nutritional status. It reflects dietary intake and skin synthesis, and it has a half-life of 3 weeks in 
serum. Vitamin D3 has a turnover rate of 2-3 months in adipose tissue [48, 50]. About 85-90%, 
10-15%, and 0.1% of 25(OH)D are attached to DBP, albumin or is in free form in maternal 
circulation, respectively [51]. Circulating 25(OH)D enters the kidney, as well as other types of 
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cells, for further metabolism. Recent studies observed DBP may have a role in maintaining stable 
stores of vitamin D metabolites by modulating bioavailability and the rate of vitamin D 
activation [52, 53]. 
Other hydroxylating reactions on 25(OH)D produces the active form of vitamin D, 
1,25(OH)2D (1,25-dihydroxyvitamin D or calcitriol). These reactions occur predominately in the 
kidney, as well as in cells in the skin, breast, colon, prostate, and brain and in monocytes and 
macrophages, catalyzed by 1 alpha-hydroxylase (encoded by CYP27B1; cytochrome P450 
enzyme, family 27, subfamily A, polypeptide 1) [27]. Both 1,25(OH)2D and 25(OH)D can be 
catabolized by proteins encoded by CYP24A1, serving as a feedback loop to avoid vitamin D 
toxicity. Specifically, toxicity is avoided when the protein hydrolyzes 25(OH)D and 1,25(OH)2D  
into 24,25(OH)2D, and 1,24,25(OH)3D, respectively [29]. 
1,25(OH)2D has nongenomic and genomic roles in the body by attaching to the vitamin D 
receptor (VDR) expressed in target organs and cells [54]. In a genomic response, a heterodimer 
complex is formed by VDR, 1,25(OH)2D, and retinoid-x receptors (RXRA). The heterodimer 
complex binds to hormone response elements on DNA, up-regulating gene expression at the 
transcriptional level and influencing important biological mechanisms in the human body [29]. 
For nongenomic responses, 1,25(OH)2D attaches to VDR exerting rapid effects in a variety of 
cell types. These nongenomic roles include regulating calcium and phosphate metabolism, renal 
reabsorption, and bone remodeling [54]. 
2.1.2 Metabolism in pregnancy 
Compared with non-pregnant adults, vitamin D metabolism is more complex in pregnancy [55]. 
Maternal 25(OH)D concentration levels are not affected in pregnancy [56, 57]. From animal 
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studies we know 25(OH)D enters placental cells by endocytosis of DBP-25OHD, by diffusion of 
free hormone, or by both mechanisms [58]. Indeed, human cord blood concentrations of 
25(OH)D equal 75 to 90% of maternal 25(OH)D concentration [56, 59]. In contrast, the 
physiologically active metabolite 1,25(OH)2D does not readily cross the placenta. Instead 
25(OH)D that passes the placenta can be hydrolyzed into 1,25(OH)2D by enzymes encoded by 
CYP27B1 expressed in maternal decidua cells [55]. Unlike maternal 25(OH)D, maternal 
1,25(OH)2D levels increase in the first and second trimester. This change may be due to the 
increased circulating vitamin D binding protein (DBP increases from 7 to 152% in pregnancy) 
and increased hydroxylation reactions in maternal kidneys [59]. 
2.1.3 Determinants of Vitamin D status 
Serum 25(OH)D concentration is influenced by exposure to solar radiation and oral vitamin D 
intake. Approximately 80% of serum 25(OH)D is derived from exposure to UVB radiation [60]. 
When UVB is absorbed, thermal isomerization converts 7-dehydrocholesterol to 
precholecalciferol and to cholecalciferol. Decreased skin absorption of UVB occurs in the winter 
months at higher latitudes, and with use of sunscreen or UVB-protective clothing [61, 62]. 
Additionally, UVB is absorbed by melanin, the primary determinant of skin pigmentation [45]. 
This absorption decreases the amount of UVB available for photolysis in vitamin D synthesis; 
therefore there is a higher risk of vitamin D deficiency among individuals with deeper skin 
pigmentation. When sun exposure is limited, oral intake of vitamin D sources such as vitamin 
supplementation, fortified milk or orange juice, as well as fatty fish, can be major sources of 
vitamin D [63]. The recommended daily allowance (RDA) of vitamin D is 600 IU/day for men 
and women up to 70 years of age [64]. Prenatal vitamins contain less than the RDA; instead they 
8 
typically contain 400 IU of vitamin D3. Additionally, serum 25(OH)D concentrations are lower 
in individuals who are older or obese [65].  
2.1.4 Vitamin D deficiency definitions 
The concentration levels of 25(OH)D to achieve optimal health is controversial. According to the 
Institute of Medicine (IOM), evidence has not established the amount 25(OH)D concentration  
needed to achieve non-skeletal health status [66]. Therefore, the IOM base their recommendation 
of 25(OH)D serum concentration levels on bone health which is 25(OH)D 40 nmol/L-50 nmol/L 
[66]. In comparison, the Endocrine Society and several experts in the field advise that 25(OH)D 
≥75 nmol/L is required for overall health [60, 67-69]. Due to this controversy, studies on vitamin 
deficiency use various cut-offs of 25(OH)D. 
2.1.5 Prevalence of Vitamin D Deficiency 
Prevalence of vitamin D deficiency depends on the definition used. In the United States, the 
prevalence of vitamin D deficiency, defined as 25(OH)D <50 nmol/L, among adults is between 
35-40% [70, 71]. Furthermore, 82.1%, 69.2%, and 30.9% of blacks, Hispanics, and whites are 
deficient. Overall, there has been an increase in the prevalence of vitamin D deficiency in the 
United States. According to data from two National Health and Nutrition Examination Surveys 
(NHANES III 1988-1994 and NHANES 2001-2004), the prevalence of 25(OH)D concentration 
levels below 50 nmol/L increased from 22% in 1988-1994 to 36% in 2001 -2004 [72]. From the 
1988-1994 data collection, prevalence of deficiency was 5 times more likely in blacks compared 
to whites. However, the difference was 10-fold in the 2001-2004 data collection. 
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2.1.6 Prevalence of Vitamin D Deficiency in Pregnancy 
In the 2001-2004 NHANES data collection, 28% of pregnant women had 25(OH)D <50 nmol/l 
compared to 37% in non-pregnant women ages 12-44 years of age [73]. Several studies have 
noted a racial disparity in 25(OH)D deficiency in pregnancy. In a cohort from South Carolina, 
75%, 30%, and 12% of African American, Hispanic, and Caucasian pregnant women, 
respectively, were vitamin D deficient in South Carolina (defined as 25(OH)D <50nmol/L ) [74]. 
In Pittsburgh, 29.2% and 54.1% of black mothers were vitamin D deficient and insufficient, 
while 5% and 42.1% of white mothers were deficient and insufficient (defined as 25(OH)D 
<37.5nmol/L and 25(OH)D 37.5nmol/L – 80 nmol/L) [75]. Overall, nationally vitamin D 
deficiency is common in pregnancy and there is strong evidence of a racial disparity. 
2.1.7 Traditional and Nontraditional roles of Vitamin D 
Vitamin D has various roles in the human body which can be divided into classical and non-
classical actions. Classical actions include regulating calcium and phosphate homeostasis, and 
developing and maintaining bone health [76]. Non-classical actions include proliferating and 
differentiating cells, apoptosis, and immunomodulatory and anti-proliferative effects through the 
autocrine and paracrine pathways [77]. Vitamin D deficiency has been associated with traditional 
outcomes such as skeletal mineralization, but also non-traditional outcomes involving the renin-
angiotensin system and inflammation (e.g., asthma, depression, bronchiectasis, bone health, 
cancers, cardiovascular disease, and diabetes) [1-8]. One of these outcomes includes 
preeclampsia. 
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2.2  PREECLAMPSIA 
2.2.1 Definition of Preeclampsia 
Preeclampsia is defined by new-onset hypertension and proteinuria after 20 weeks gestation. 
Specifically, preeclamptic women have systolic pressure greater than 140 mm Hg and/or 
diastolic pressure above 90 mm Hg. Proteinuria in preeclamptic women is characterized as 
having protein greater than 300 mg in a 24-hour urine sample. Preeclampsia can be further 
classified as early-and late-onset, as well by severity (mild and severe). Early-onset preeclampsia 
occurs at or before 33 weeks of gestation while late-onset occurs at 34 weeks of gestation or 
later. Severe forms of preeclampsia include cases with additional symptoms including severe 
hypertension, increased liver enzymes in blood, kidney dysfunction, high levels of proteinuria, or 
stroke. 
2.2.2 Prevalence of preeclampsia 
Currently, preeclampsia occurs in 2-8% of pregnancies in the United States [78]. Despite the low 
prevalence, preeclampsia is a public health concern due to the 25% increase in prevalence from 
1987 to 2004 [79]. More specifically, the prevalence of severe preeclampsia in 2010 has 
increased by 322% (0.3% to 1.4%) since 1987 while prevalence has decreased for mild 
preeclampsia (3.1% to 2.5%) [80]. In addition, late-onset is more common in pregnancy (90%) 
compared to early forms of the disease [81]. 
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2.2.3 Consequences 
Preeclampsia is a multi-systemic condition which may cause organ failure, seizure, stroke, or 
even death to the mother [78]. However, fetal and maternal outcomes depend on severity and 
onset of disease. Women with early-onset and severe forms of preeclampsia have an increased 
risk of preterm birth, fetal death, recurrence of preeclampsia and increased risk of stillbirth in a 
subsequent pregnancy [82, 83]. In early-onset cases, there is a higher risk of infants being born 
small-for-gestational age, while there is a higher risk of large-for-gestational age in late-onset 
cases [84, 85]. In severe cases, preeclampsia can also be a life-threatening disease which is 
responsible for 16% of maternal deaths in high income countries. The risk of mortality is 3.1 
times greater in blacks with preeclampsia as whites with preeclampsia [86]. 
2.2.4 Risk Factors 
Risk factors for preeclampsia include chronic hypertension, kidney disease, black race, obesity, 
diabetes, younger age, and nulliparity [87]. In addition to these factors, there is a 2- to 5-fold 
increase in preeclampsia occurrence in women with maternal history of preeclampsia, which is 
evidence of a genetic component for preeclampsia [41]. 
2.2.5 Prevention and Treatment 
Preeclampsia is a life-threatening disease for the mother and fetus due to a lack of management 
leading to preeclampsia [88]. Preventive agents have been tested in preeclamptic women, such as 
low-dose aspirin, vitamin E and C, and calcium supplements [89, 90]. In high risk women, there 
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is evidence that low-dose aspirin and calcium decreases risk of preeclampsia. Unfortunately, 
delivery of the placenta is the only cure for preeclampsia [91]. 
2.2.6 Pathophysiology 
Preeclampsia is a two-stage process. The first stage occurs in early pregnancy during the 
development of the placenta. In preeclampsia, poor placental perfusion results from abnormal 
trophoblast invasion, poorly remodeled spiral arteries and limited utero-placental circulation 
[92]. In addition, there may be a maternal-fetal immunologic maladaptation that may cause poor 
placental perfusion [93]. The reduced utero-placental blood flow can lead to ischemia, oxidative 
stress, inflammation and endothelial dysfunction. Hypoxia increases production on several 
angiogenic and growth factors, favoring an antiangiogenic state [92]. This includes an increase in 
anti-angiogenesis factors sVEGFR-1 and sEndogin, and a decrease in factors that promote 
angiogenesis like PIGF and VEGF. Clinical symptoms of preeclampsia occur in stage 2 when 
anti-angiogenic factors cross the placenta and enter maternal circulation causing a systemic 
inflammatory response [94]. These factors can impair endothelial cell function resulting in a 
reduced stimulation of the renin-angiotensin system, vasoconstriction, and hypertension. 
2.2.7 Vitamin D and Preeclampsia 
Vitamin D deficiency may impact preeclampsia risk through several biological mechanisms.  
These mechanisms include placentation, endothelial function, as well as the renin-angiotensin-
aldosterone system [38, 95, 96]. There are several mechanisms important to the development of a 
healthy placenta that involves vitamin D metabolites. Vitamin D metabolites regulate genes 
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important for implantation (HOXA10), trophoblast invasion, as well as anti-inflammatory 
responses in maternal decidua and fetal trophoblasts [38]. Vitamin D sufficiency helps maintain 
an appropriate inflammatory response and maternal-fetal interface by promoting an innate 
response to infection and by preventing an over-reactive inflammatory adaptive immunity [97]. 
Also significant in the development of a normal placenta, 1,25(OH)2D has a role in 
decidualization by transforming endometrial cells into decidual cells[38]. This process is vital for 
proper implantation in early pregnancy. Vitamin D sufficiency also maintains endothelial 
function by limiting production of proinflammatory cytokines [98]. Limiting cytokine production 
in the presence of vitamin D sufficiency may reduce endothelial damage and reduce the amount 
of factors released into maternal circulation. In addition, vitamin D regulates angiogenesis 
through a direct effect on vascular endothelial growth factor (VEGF) gene transcription 
impacting endothelial cell function [99]. More specifically, 1,25(OH)2D increases VEGF 
production in vascular smooth muscle cells by binding to response elements in the promoter 
region of the gene[100]. In vitamin D deficient women, this regulation may be disrupted causing 
endothelial dysfunction. Lastly, 1,25(OH)2D has an important role in regulating the renin-
angiotensin-aldosterone system (RAAS) by suppressing renin and angiotensin levels through 
VDR. In vitamin D deficient people, studies have found evidence of deregulated RAAS and 
increased oxidative stress and high blood pressure [96, 101]. 
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2.2.8 Studies on Vitamin D and preeclampsia 
2.2.8.1  Vitamin D supplementation 
There is limited research on vitamin D supplementation in pregnancy. Hollis et al did not find a 
significant difference in preeclampsia by vitamin D supplementation group (400 IU/day, 2000 
IU/day or 4000 IU/day)[102]. The lack of significance may be due to starting supplementation 
too late in pregnancy to reduce the risk of preeclampsia. In the follow-up trial, there were only 4 
cases of hypertension related pregnancy outcomes which included preeclampsia cases [103]. Due 
to this small number of cases, no significant difference between supplementation groups could be 
detected. Future randomized control trials (RCT) are needed using vitamin D supplementation in 
earlier pregnancy and using larger sample sizes. 
2.2.8.2 Observational studies on vitamin D and preeclampsia 
Two meta-analyses of observational studies determined an association between low 25(OH)D 
and risk of preeclampsia. However, both noted heterogeneity among studies [17, 18]. In one of 
these meta-analysis, there was an indication for a strong between-study heterogeneity on 8 
observational studies (I2 = 52.7%; P = 0.039)[13, 14, 16, 20, 23, 24, 104, 105]. Indeed, a sub-
meta-analysis reported a significant association between 25(OH)D <50 nmol/L cut-point for 
deficiency and preeclampsia risk[20, 24, 104, 105], and no significant association between 
women with 25(OH)D <37.5 nmol/L  and risk of preeclampsia [13, 16, 23, 75].  In addition, 
studies conducted in the U.S had a significant association while those outside the U.S were not 
significant. There were no differences by study type (cohort, nested-case-control, cross-sectional, 
and case-control studies). In another meta-analysis, investigators reported a pooled odds ratio of 
0.52 (95% CI 0.30-0.89) with evidence of heterogeneity between studies (I2=60%, P=0.02)[18]. 
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Only studies that reported adjusted estimates were included in the meta-analysis [13, 14, 20, 23, 
24]. All 5 of these studies used the same definition of preeclampsia.  When subdividing the 
studies by latitude, the investigators only determined an association for studies located < 45 ◦N; 
however there was no difference by study size, assay or trimester of blood collection. In 
contradiction to the previous meta-analysis, there was no difference in effects for studies using 
25(OH)D <37.5 or 25(OH)D <50 nmol/L as 25(OH)D cut-points. Overall, both studies suggest 
an association between higher serum 25(OH)D and a reduced risk of preeclampsia despite the 
heterogeneity between studies. 
A recent nested case-control study was not included in either meta-analyses [25]. These 
investigators measured 25(OH)D at <20 weeks gestation among 169 preeclampsia cases and 
1,975 controls. They reported a dose-response relationship between increasing maternal 
25(OH)D levels and decreasing risk of preeclampsia. The relationship had a plateau at 25(OH)D 
=50 nmol/L after adjusting for confounders. In addition, there was a 2-fold increased risk of 
preeclampsia in women with 25(OH)D <30 nmol/L compared with those who had 25(OH)D ≥ 50 
nmol/L. These results indicate very low 25(OH)D (<30 nmol/l) may be an important modifiable 
risk factor to preeclampsia. 
2.2.8.3  Severe Preeclampsia 
Vitamin D deficiency may be important in severe preeclamptic cases. Baker et al conducted a 
nested case-control study with 51 severe preeclampsia cases and 201 controls[24]. The odds 
increased 5-fold for women with 25(OH)D<50nmol/L at 15-20 weeks of gestation compared 
with women with 25(OH)D >50 nmol/L (OR 5.41 95% CI (2.02, 14.52)). In a separate case-
cohort study, Bodnar et al reported vitamin D deficiency to be a risk factor for severe 
preeclampsia in a study population with 57% 25(OH)D < 50 nmol/L[15]. There was a 40% 
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reduced risk for severe preeclampsia in women who had 25(OH)D ≥ 50nmol/L compared with 
25(OH)D < 50 nmol/L (OR 0.65 95% CI (0.43, 0.98)). A study further subdivided severe 
preeclampsia into early-onset preeclampsia[105]. Investigators used 50 participants with early-
onset preeclampsia with severe symptoms and 100 controls matched on race and gestational age 
of sample collection. There was a 63% decreased odds of preeclampsia per every 25 nmol/L 
increase in 25(OH)D concentration, after adjusting for BMI, maternal age, race, and gestational 
age (OR 0.37 95% CI 0.22, 0.62 ). These findings may indicate the importance of investigating 
25(OH)D and preeclampsia risk by preeclampsia subtype. 
2.2.9 Conclusion 
Overall, observational studies suggest low 25(OH)D concentration in serum is associated with 
increased risks of preeclampsia and severe preeclampsia. However, there is evidence of 
heterogeneity of the association between the studies. Future studies should explore the 
association of vitamin D deficiency and preeclampsia by subtype due to the heterogeneity of the 
disease. 
VITAMIN D AND GENETICS 
There is evidence of a genetic contribution of circulating 25(OH)D concentration. Data on twin 
studies and family based studies estimated heritability of vitamin D status to be 23-80% [106, 
107]. Due to the importance of vitamin D in pregnancy health, there needs to be effort to 
determine the genetic determinants of vitamin D deficiency in pregnancy as well as outcomes 
17 
like preeclampsia. The following reviews three important vitamin D metabolism candidate 
genes: GC, CYP27B1, and VDR. 
2.3.1 GC gene 
The vitamin D metabolites 25(OH)D and 1,25(OH)2D circulate in blood by attaching to 
vitamin D binding protein (DBP). DBP is a protein encoded by GC gene or group-specific 
component gene which is located on 4q12-q13 in the human genome on the reverse strand. The 
protein can be found in plasma, ascitic fluid, and cerebrospinal fluid and on the surface of many 
cells, which bind and transport vitamin D and metabolites of vitamin D to target tissues. In 
serum, half-life of DBP is 2.5-3 days. In the ‘free-hormone-hypothesis’, only the unbound 
25(OH)D is bioavailable while DBP modulates and circulating free and bioavailable 25(OH)D 
concentration [108]. However, this might be a simplification for vitamin D [109]. There are 
reservations for this hypothesis in relation to vitamin D metabolites, including evidence that 
serum concentrations of free 1,25(OH)2D is much less than the concentrations normally bound to 
VDR [110, 111]. Indeed, evidence support DBP is important in maintaining levels of 25(OH)D 
and 1,25(OH)2D in serum, as well as modulating the bioavailability of these metabolites to 
peripheral tissues [52]. In addition, DBP bound 25(OH)D may be needed for 25(OH)D 
acquisition in some cells [112-114], and a randomized control trial reported serum 25(OH)D 
concentration is still the best metric of vitamin D status despite the free hormone hypothesis 
[115]. 
Transportation of vitamin D metabolites may be affected by variations in the GC gene. 
DBP is highly polymorphic in humans. Variations in GC gene is associated with varying 
25(OH)D levels, and modulates DBP levels and affinity for 25(OH)D [116]. Poor binding may 
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reduce the 25(OH)D concentration and other vitamin D metabolites in serum, while low DBP 
concentration may increase risk of vitamin D deficiency when vitamin D sources are scarce 
[117]. In DBP null mice, vitamin D deficiency is rapidly developed when fed a low vitamin D 
diet [118]. This phenomenon may be important for disease risk by reducing the amount of 
1,25(OH)2D in serum. Studies have reported increased risk of disease for some variants in GC 
gene, including breast cancer, prostate cancer, colorectal neoplasm, COPD, and Grave’s disease 
[119-123]. Below is a summary on the effects of GC variants on 25(OH)D levels in non-
pregnancy. To date, there are no studies on 25(OH)D concentration and GC variants in 
pregnancy, as well as studies on the effects of GC variants on pregnancy outcomes.  
2.3.1.1  Association with 25(OH)D in non-pregnant adults 
Nine studies examined GC variants and vitamin D concentration in non-pregnant adults 
(Appendix Section: Table 1) including two genome-wide studies [31, 119, 122-136]. The most 
consistent results occurred for two missense mutations: rs4588 and rs7041. The mutation variant 
rs4588 results in a threonine to lysine amino acid change at position 420, while rs7041 results in 
an aspartic acid to glutamic acid change at amino acid position 416 [137]. Two other variants, 
rs2282679 and rs1155563, are commonly used as a proxy to rs4588 due to high linkage 
disequilibrium [124, 126]. 
Consistently, carriers of the rs4588 C allele had lower 25(OH)D concentration.  The SNP 
rs4588 was associated with serum 25(OH)D levels in Polish [138], Canadian, and American 
(white, Hispanic and African Americans) [22, 133, 139], Dutch [122], British [140], and Han 
Chinese [141] adults. Mean 25(OH)D concentrations differed by genotype and per risk allele. In 
addition, both rs4588 and rs2282679 genotypes had genome-wide significance in two genome-
wide association studies [124, 126]. These studies provide stronger evidence that these variants, 
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or variants in linkage disequilibrium with these variants, are important in predicting 25(OH)D 
levels. More specifically, one GWAS reported a 49% increased risk for vitamin D deficiency for 
the minor allele of rs2282679 in Caucasian participants [124]. 
There is consistent evidence indicating 25(OH)D concentration is lower in those who 
carry the rs7041 T allele [126, 129-131, 133, 142]. In two studies, participants carrying two 
rs7041 variants had the lowest mean concentration of 25(OH)D while wild-type carriers had the 
highest mean[126, 131]. Furthermore, there was a decreased 25(OH)D concentration per risk 
allele in three separate studies [129, 133, 141]. The variant also reached genome-wide 
significance in two genome-wide association studies, supporting a role of rs7041 in predicting 
vitamin D status [124, 126].  
Three studies have noted 25(OH)D concentration can differ significantly by three 
common haplotypes of rs4588 and rs7041 variants [22, 119, 130]. In these studies, participants 
had lowest 25(OH)D concentration when they carried both variant alleles of rs7041 and rs4588. 
Using cross-sectional data on community-dwelling adults, investigators reported rs7041 and 
rs4588 variants accounted for 9.9% of the variation in total 25(OH)D levels, while season and 
race explained 10.5% and 7.3%[22]. Furthermore, there was large heterogeneity of rs7041 and 
rs4588 between blacks and whites in the study population. The T/C genotype (Gc1F) was 
reported in 92.7% in blacks versus 6.0% of whites, and the T/A genotype (Gc2) was reported in 
2.1% of blacks compared to 76.0% of whites. Gc1F haplotype is known for higher affinity for 
25(OH)D and low DBP, while Gc2 has a lower affinity for 25(OH)D and is associated with 
higher DBP levels[109]. These relationships may be important when low levels of DBP may lead 
to an increased risk of 25(OH)D deficiency when vitamin D sources are rare, including increased 
skin pigmentation, lack of supplementation, or food sources.  
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The remaining variants were associated with 25(OH)D for one study each: rs12512631 
(3’ downstream region of GC)[125], rs222020[128], rs2298849[31], rs3755967[131], and 
rs17467825[131]. Some of these variants are in LD with rs4588 or rs7041, while others are not. 
Unfortunately, the functional consequences of these variants are still unclear. Finding causal 
variants among the coding and promoter variants has been unsuccessful. 
2.3.1.2 Conclusions 
Overall, there is strong evidence that genetic variants in GC may have an important role in 
determining 25(OH)D levels and health outcomes. There are two common missense variants that 
impact 25(OH)D concentration in non-pregnant adults. However, studies in pregnancy are 
sparse. Due to the physiological changes in pregnancy, including increased DBP levels, studies 
in pregnancy may be informative. Researching these variants in pregnant adults is important 
since there is consistent evidence that common GC variant genotypes impact 25(OH)D 
concentration in non-pregnant adults. 
2.3.2 CYP27B1 gene 
Absorbed and synthesized vitamin D needs to hydroxylated multiple times before 
becoming the active metabolite of vitamin D. Hydroxylation of 25(OH)D to form 1,25(OH)2D is 
done by an enzyme encoded by CYP27B1. CYP27B1 encodes a protein from a family of 
cytochrome 450 enzymes. Variations in the gene may influence 25(OH)D and 1,25(OH)2D 
serum concentration by changing the rate of hydroxylation[143]. Variants in CYP27B1 have 
been noted to cause a deficiency in 1,25(OH)2D leading to a disorder known as vitamin D-
dependent rickets[144]. Other diseases related to CYP27B1 include multiple sclerosis, type 1 
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diabetes, and Addison’s disease [140, 145-147]. Summarized below are studies on 25(OH)D 
concentration in non-pregnant adults, as well as one pregnancy related study. 
2.3.2.1 Association with 25(OH)D in non-pregnant adults 
The relationship of CYP27B1 variants with 25(OH)D were assessed in several RCTs and 
observational studies (Appendix Section: Table 2)[31, 128, 129, 134, 135, 148-150].  However, 
only a few studies reported differences in 25(OH)D concentration by CYP27B1 genotype. Other 
studies had low coverage of variants included in the genotyping process [125, 129, 139]. Low 
coverage limits the ability of the study to find an association. Also, small sample sizes limited 
the ability of these studies to detect a difference by genotype. 
Rs10877012 is one variant in CYP27B1 that was associated with varying 25(OH)D 
concentration levels [31, 151]. This variant is a promoter polymorphism (position 1260) which 
may affect 25(OH)D concentration by reducing synthesis of 1,25(OH)2D[152].  In one study, 
wild-type carriers had higher concentration of 25(OH)D compared to the variant carriers in 
summer and autumn seasons[151]. There was no association in winter or spring. This seasonal 
difference may be due to an increased 25(OH)D load in summer months when skin synthesis of 
vitamin D is highest[151]. A separate study described African-American variant carriers as 
having decreased 25(OH)D concentration compared to wild-type carriers[31]. The allelic 
frequency for the variant is highest only in African-Americans which may increase the power of 
detecting an association in African-Americans compared to other races. One study on pregnant 
women with gestational diabetes mellitus also suggest a difference in 25(OH)D concentration by 
CYP27B1 genotype (rs10877012) (Appendix Section: Table 4)[148]. Overall, there is evidence 
that promoter region variant of CYP27B1 gene may be an important risk factor for vitamin D 
deficiency.  
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Carriers of two other variants in CYP27B1 were reported to have different 25(OH)D 
concentration by genotype[153]. 25(OH)D concentration was increased for carriers of 
rs703842(C/T) or carriers of rs4646536(C/T) in a Canadian multiple sclerosis study. 
Unfortunately, the effects of these variants were not repeated in other studies which may have 
had poor coverage of the two variants as well different ethnicities/races (Hispanic and African 
Americans). 
2.3.2.2 Conclusions 
Only one variant in CYP27B1 has been repeatedly associated with 25(OH)D concentration in 
non-pregnant adults. It is biologically plausible for CYP27B1 to influence 25(OH)D 
concentrations as it converts 25(OH)D to its active hormone, 1,25(OH)2D. The lack of 
association in other studies may be due to small sample sizes and poor genotype coverage of 
candidate genes. Future studies using larger sample sizes and more gene coverage are needed to 
replicate these findings. 
2.3.3 VDR gene 
The VDR gene, which spans 63.49 kb on the reverse strand of chromosome 12q12-q14, is 
another candidate gene for vitamin D metabolism. Through VDR, 1,25(OH)2D regulates up to 
3% of the human genome which include functions in growth regulation, DNA repair, 
differentiation, apoptosis, membrane transport, metabolism, cell adhesion, and oxidative 
stress[118]. The gene is expressed in almost every human tissue; although at different 
concentrations[154]. The VDR is a nuclear receptor for steroid hormones and mediates its action 
via two main methods, one of which is at the gene expression level and the other a more rapid 
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non-genomic response involving signaling cascades[28]. The active metabolite, 1,25(OH)2D, is 
transported by DBP to target cells that express vitamin D receptors. VDR gene encodes this 
nuclear hormone receptor for 1,25(OH)2D. After 1,25(OH)2D interacts with VDR, RXR attaches 
to the complex which forms a heterodimer. The heterodimer complex activates expression of 
genes involved in important biological mechanisms, like bone homeostasis and the inflammation 
process. These processes may be altered by variations in the VDR gene making up several 
important and common genotypes [118]. The list of diseases associated with VDR variants is 
extensive and includes multiple sclerosis, prostate cancer, breast cancer, and heart disease[155-
158]. 
2.3.3.1 Association with 25(OH)D in non-pregnant adults 
Three VDR variants were associated with serum 25(OH)D levels, including rs2228570 
(previously known as rs10735810), rs2544037, and rs10783219 (Appendix Section: Table 3).  
The rs2228570 variant modifies the translation initiation site on VDR, changing the function of 
the receptor. The mutation changes the threonine into cysteine in the first initiation codon 
(ATG), introducing a FokI site to exon 2 and creating a restriction site. The presence of the 
restriction site creates a longer VDR protein isoform which has lower transcriptional activity than 
in the absence of the restriction site. Consistently, the variant carriers of Fok1 have higher serum 
levels compared to wild-type healthy individuals[32, 159].  
Another important variant is rs2544037, which may be in linkage disequilibrium with a 
functional unknown variant in VDR. Wang et al conducted a Z-score weighted meta-analysis 
across several cohorts and reported an association for this variant; however the significance was 
lost in the replication cohort of 9366 participants[160]. The lack of replication may mean the 
variant is not the functional variant. Instead, it may be in linkage disequilibrium with the 
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functional variant. Carriers of a third variant, rs10783219, had a lower concentration of 25(OH)D 
compared to wild-type individuals. This association was also noted in a Hispanic subpopulation 
living in San Antonio (beta= -0.164; 95% CI -0.108,  -0.272)[161]. However, the finding may be 
population specific since it was not replicated in two subpopulations in the same study. 
One study on pregnant women assessed 4 VDR variants: ApaI, BsmI, FokI and TaqI. In 
the cohort of 354 women, 25(OH)D was also analyzed at 28-30 weeks of gestation[42]. The 
investigators did not find maternal 25(OH)D varied by genotype. However, this study was 
limited by small sample size for ApaI aa, Bsm1 bb and TaqI tt genotypes (n=2, 2, and 1, 
respectively) and by the small number of genotyped SNPs. 
Overall, there was some evidence that VDR variant carriers may be associated with 
different levels of 25(OH)D concentration compared to wild-type individuals. However, two of 
the three variants might not be the functional variants underlying the association. Other studies 
did not find an association due to poor coverage of the VDR gene. 
2.3.3.2 Variants and Pregnancy or Infant outcomes 
Many studies attempted to detect a difference in risk of pregnancy and infant outcomes by VDR 
genotype, including one study on preeclampsia (Supplementary Section: Table 4). These 
pregnancy studies were limited by low sample size and poor coverage by genotyping only 1 to 4 
polymorphisms in the VDR gene (Apa1, Bsm1, Fok1 or Taq1) [43, 162-164]. In addition, since 
the actions of 1,25(OH)2D are influenced by VDR, it is important to measure  and test vitamin D 
status as a confounder and possible effect modifier in these studies[155]. However, some of these 
studies did not measure 25(OH)D concentration [43, 165]. 
Several limitations in the study on preeclampsia may have limited power to report an 
association[43]. In Brazil, investigators conducted a study on women who were healthy (n=213), 
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diagnosed with gestational diabetes (n=154), and diagnosed with preeclampsia (n=164). Only 
three polymorphisms were genotyped: FokI, ApaI and BsmI. There was no difference by 
maternal genotype, allelic, and haplotype frequencies between the three groups of participants. 
The study may have missed functional variants important to the development of preeclampsia by 
limiting to three polymorphisms. In addition, this study did not measure 25(OH)D concentration 
levels. Overall, there was a lack of association perhaps due to several important limitations. 
Unlike the preeclampsia study, a nested case-control study reported FokI variant carriers 
had increased odds for preterm birth for a population of Israeli women[165]. This study 
genotyped DNA for four SNPS (FokI, ApaI, TaqI, and BsmI) from 33 cases of spontaneous 
preterm birth (<35 weeks of gestation) and 98 controls. The frequency of TaqI and FokI varied 
by case status. However, only the FokI variant significantly increased risk for preterm birth in 
the additive approach. More specifically, using exact logistic regression, the maternal FokI 
variant carriers had a 3-fold increased odds of spontaneous preterm birth compared with wild-
type carriers (OR=3.3 95% CI (1.1-9.6)). Furthermore, the study reported neonatal variation in 
VDR did not affect preterm birth risk; instead only maternal genotype impacted risk. The study 
did not measure 25(OH)D concentration; therefore, residual confounding may be present. 
Offspring birth size was examined using 25(OH)D status measured at 28-30 weeks of 
gestation[162]. Despite a lack of association between genotype and vitamin D status(as 
previously discussed), investigators noted evidence of effect modification by infant FokI 
genotype. For this study, the effect of maternal vitamin D status on birth size was analyzed by 
FokI, ApaI, Bsm1, and Taq1 genotypes. In infants with FF/Ff genotype, vitamin D deficiency 
(25(OH)D <28 nmol/L) was associated with low birth weight compared with women with 
25(OH)D >28 nmol/L (3296 g versus 3584 g; p=0.02). This finding was not repeated for ff 
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genotype. An important limitation for this study is the low sample size since only 1-2 infants 
carried ApaI aa, Bsm1 bb, or TaqI tt genotypes. Overall, this study reported differences of 
association of 25(OH)D status on birth size by VDR genotype. This may be evidence that 
25(OH)D load is important when considering the effect of VDR variation on birth outcomes. 
Several SNPs were genotyped in a nested case-control study on the risk for small-for-
gestational age by maternal genotype[166]. Small-for-gestational age (SGA) was defined as a 
live-born infant with less than the 10th percentile of birth weight based on gender and age of a 
reference population at Magee-Womens Hospital. In this study, 124 cases of SGA and 1074 
controls were recruited less than 16 weeks of gestation. The investigators genotyped 70 tagging 
SNPs on and around the VDR gene. One of these variants, rs11168292, was associated with SGA 
in white participants. For every allele, the odds for SGA increased by 70% while controlling for 
25(OH)D (OR=1.7; 95%CI 1.1, 2.8). In black participants, there were three variants that were 
significantly associated with SGA when controlling for 25(OH)D. These included rs11168287, 
rs2239179, and rs3782905. Carriers of minor alleles of rs11168287 had a 60% decreased odds of 
SGA compared to wild-type individuals, while rs2239179 carriers had a 70% decreased odds of 
SGA (OR 0.4 95%CI 0.2,0.8); OR 0.3 (0.1,0.7)). On the contrary, carriers of rs3782905 had 
almost a 6-fold increased odds of SGA (OR 5.3, 95%CI 1.8, 17.4). These variants may be 
important predictors for small-for-gestational age independent of 25(OH)D concentration; 
however, there are no other published studies on SGA and VDR variants. 
There was a difference in low birth weight by maternal VDR genotype where low birth 
weight was defined as a live born infant weighing less than 2500 grams at birth[167]. Swamy et 
al examined the effects of 38 VDR polymorphisms on birth weight in a cohort of pregnant 
women recruited between 18 and 28 weeks of gestation. They selected haplotype tagging SNPs 
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for Yoruban and Caucasian populations of the HapMap Project. Using tagging SNPs from both 
populations increased representation for both blacks and whites in the study population. One 
variant was significantly associated with low birth weight in non-Hispanic blacks (rs7975232; 
p=0.0009). This association was not seen in non-Hispanic whites. The investigators did not 
measure 25(OH)D concentration; therefore, the association may have residual confounding. 
2.3.3.3 Conclusion 
Currently, there is no evidence that VDR SNPs impact 25(OH)D concentration in 
pregnancy. However, studies have reported VDR SNPs may have a role in preterm birth, low 
birth weight, SGA, and birth size. More research is needed to find if VDR genotypes are 
important in the development of preeclampsia. There are several limitations on these pregnancy 
studies such as limited number of SNPs, not controlling for 25(OH)D concentration, and small 
sample size. Replication is needed to determine if findings are repeatable and generalizable in 
other study populations.  
2.3.4 Functional variants 
There were three variants that have a functional significance in pregnancy, rs10877012 
(CYP27B1), [148] [148] rs10735810 (commonly known as Fok1 in VDR), and rs7975232 (VDR). 
Variant rs10877012 is a promoter polymorphism which may change the conversion of 25(OH)D 
to 1,25 (OH)2D, subsequently changing the amount of 1,25(OH)2D. The Fok1 variant modifies 
the translation initiation site on VDR, changing the initiation site into a restriction site. The intron 
variant, rs7975232, is part of a haplotype that is associated with mRNA stability[167]. A change 
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in mRNA stability can affect the amount of protein produced. These variants may play an 
important role in vitamin D deficiency in pregnancy as well as pregnancy outcomes. 
2.4  CONCLUSION 
Overall, more research is needed to determine if risks of vitamin D deficiency and preeclampsia 
vary by risk allele. Past research has shown variants of GC, CYP27B1 and VDR genes are 
variable between people which may affect 25(OH)D levels. Furthermore, there is increasing 
evidence that genetics may have an important role in several pregnancy and birth outcomes. 
However, there are several limitations including poor gene coverage, small sample sizes, and not 
controlling for 25(OH)D concentration. Our goal is to fill in these knowledge gaps by using 
samples and data from two large pregnancy studies. 
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Table 1: Risk variants on GC gene for vitamin D deficiency in non-pregnant adults 
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rs12512631 Case-control By genotype 749 cases 
(prostate cancer) 
and 781 controls 
USA Ahn, 2009[125] 
rs17467825 Cohort By genotype 9528 Norway Jorde, 2012[131] 
rs222020 Cohort Per risk allele 156 Bu, 2010[128] 
rs2298849 Cohort By genotype 792 USA Signorello, 
2011[31] 

















Table 2: Risk variants on CYP27B1 gene for vitamin D deficiency in non-pregnant adults 























rs4646536 Twin-study Per risk 
allele 
198 Canada Orton, 2008[149] 
rs7033841 Twin-study Per risk 
allele 
198 Canada Orton, 2008[149] 
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Table 3: Risk variants for vitamin D deficiency on VDR in non-pregnant adults 
Variant Type of study Type of 
effect 
Sample size Population Authors 
rs10783219 Family-study Per risk 
allele 


























Table 4: Risk variants for infant and birth outcomes 






























per allele White women: 
     Rs11168292 
          OR=1.70 CI  (1.1,2.8) 
Black women: 
     Rs11168287 
          OR=0.40 CI  (0.2,0.8) 
     Rs3782905    
          OR=5.30 CI  (1.8,17.4) 
     Rs2239179   
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Cohort Australia VDR: 
rs10735810 
By genotype Subscapular skinfolds: 
     ff versus Ff or F 
          5.7 versus 6.4mm 
CI for difference (-1.2-0.3) 
Suprailiac skinfolds: 
     Ff versus Ff or FF 
          6.3 versus 7.0 mm 
CI of difference(-1.2, -0.2) 
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Table 5. Risk variants for pregnancy and infant health outcomes. 















Brazil NA N/A N/A 
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birth weight Cohort 615 USA VDR: 
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CC 68 (47.9) [n(%)] 
CA 62 (43.7)  
AA 12 (8.5) 
>50 nmol/L 
CC 31 (38.8) 
CA 31 (38.8) 









3 . METHODS 
3.0  STUDY POPULATION
We will use two study populations to achieve our research goals: EVITA and CPP. The first aim 
will use a case-cohort study called EVITA. The genetic aims (aims 2 and 3) will use an 
additional study called Collaborative Perinatal Project (CPP). Candidate gene association studies 
are traditionally case-control studies using healthy controls [169]. Therefore, we will only use 
healthy controls for our genetic aims following a case-control design. We will combine the two 
studies (EVITA and CPP) through a meta-analysis. Separately, the two study populations have a 
potential for false positives and false negatives due to small sample size. By using a meta-
analysis approach on the two study populations, we will increase power to find an association 
with risk variants. In addition, by using a diverse cohort (CPP), there will be more power to 
detect an association for variants commonly found in mothers with African ancestry. 
EVITA uses data and banked serum samples from women who had aneuploidy screening 
at ≤20 weeks gestation and delivered at Magee-Womens Hospital of UPMC in Pittsburgh, 
Pennsylvania. These samples were collected and stored in -80◦C freezers. Pregnancies that were 
eligible for this study were identified after merging a validated perinatal database that contains 
clinical information on all hospital deliveries with a database of all pregnancies that received 
screening at the hospital’s Center for Medical Genetics and Genomics. This case-cohort study 
uses 650 preeclampsia cases, as well as 2327 randomly selected subcohort. The subcohort was 
selected from 65,867 singleton live-born infants. The subcohort was predominately non-Hispanic 
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white, college graduates, married, non-smokers, and covered by private insurance at the start of 
the index pregnancy (Table 1). About half of the subcohort was normal weight and were 
nulliparous before pregnancy. Compared with the subcohort, preeclampsia cases were older, and 
more likely to be Black, nulliparous, and covered by Medicaid. They also completed fewer years 
of education and had a higher prepregnancy BMI. 
The collaborative perinatal project (CPP) uses data and samples collected <26 weeks 
from 1959-65 at 12 U.S medical centers for a total of 55,908 participants. Data were collected by 
an in-person interview (sociodemographic factors, medical history, and obstetric history) at first 
prenatal visit, and obstetric and medical events were recorded every 8 weeks after initial visit. In 
addition, blood samples were collected and random urine samples were tested for albumin every 
8 weeks. The case-cohort uses n=717 preeclamptic cases and 3068 in the subcohort. 5.5% of the 
total cohort was selected (Table 1). About fifty percent of the CPP subcohort was white, 50% 
smoked, and 60% were between 20-29 years old. The subcohort was predominately multiparous, 
had normal BMI, and married. Compared to the subcohort, the cases were more likely to be 
white, unmarried, had higher BMI, and completed less education. 
There are some differences between the two cohorts that should be noted. A greater 
proportion of CPP is black, multiparous, and younger, had lower BMI, completed less education, 
and had higher rates of smoking. One of the biggest advantages of using the CPP cohort in the 
genetics analysis is the high proportion of blacks in the study population. However, it is possible 
the two study populations will have different risk variants by chance. The meta-analysis 
approach will reduce any of these spurious associations. High rates of smoking in CPP may hide 
the true effects of risk variants on preeclampsia since smoking decreases risk of 
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preeclampsia[170]. Adjusting for smoking might not fully correct for this strong effect causing 
residual confounding. 
3.1  PREECLAMPSIA DEFINITIONS 
In the EVITA cohort, ICD-9 codes were used to define preeclampsia (642.4-642.7). 
Severe (642.5 and 642.6) and mild subtypes of preeclampsia (642.4) were also identified. 
Gestational age at delivery was determined by best obstetric estimate comparing menstrual 
dating and ultrasound and was ascertained from the perinatal database. Our reliance on correct 
assignment of ICD-9 codes for preeclampsia may pose as a potential source of misclassification 
of preeclampsia[171]. 
In the CPP cohort, medical records were used to define preeclampsia as gestational 
hypertension and proteinuria, and return of abnormalities to normal in the postpartum period. 
More specifically, gestational hypertension was defined new onset (>24 weeks) of two or more 
measurements of systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 
mm Hg. Proteinuria was determined by  two random urine dipsticks of 1+ protein or one dipstick 
of 2+ protein. We would expect preeclampsia to be classified more accurately for CPP than the 
EVITA cohort since the CPP cohort was followed prospectively and we used the current 
definition of preeclampsia to define cases. 
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3.2 VITAMIN D 
 In EVITA, maternal aneuploidy screening samples were held at -20°C for one month 
before transfer to -80°C for long-term storage. Only samples drawn ≤ 20 weeks of gestation were 
used for this study because this generally precedes the clinical onset of preeclampsia. An aliquot 
of each sample that was previously thawed once was sent to a Vitamin D External Quality 
Assessment Scheme–proficient (DEQAS, London, United Kingdom) and Clinical Laboratory 
Improvement Amendments–certified (Centers for Disease Control and Prevention, Atlanta, 
Georgia) laboratory. The laboratory assayed total 25-hydroxyvitamin D (25(OH)D) (calculated 
as 25(OH)D2 + 25(OH)D3) using liquid chromatography–tandem mass spectrometry[172]. Intra-
assay variation was 9.6% and the inter-assay variation was 10.9%. We will test multiple 
categories of serum 25(OH)D concentration , as well as use cubic splines, quadratic, 
quintiles[173]. In addition, we will test multiple knots and knot placements, and use two criteria 
to select the final specification (BIC, F)[174]. We will also evaluate the sensitivity of our results 
by excluding n=2 observations with 25(OH)D >175 nmol/L.  
For CPP, maternal serum samples were stored at −20°C with no recorded thaws. Random 
samples were selected from samples drawn at ≤26 weeks. Sixty-four percent of the samples were 
drawn 20-26 weeks of gestation, while 28% and 8% were drawn at 13-20 weeks and <13 weeks. 
Like EVITA, serum was shipped to the laboratory of Dr. Michael Holick and assayed for total 
25-hydroxyvitamin D (25(OH)D) [25(OH)D2 + 25(OH)D3] using liquid-chromatography-tandem 
mass spectrometry based on National Institute of Standards and Technology (NIST) standards. 
The assay had a coefficient of variation of 6.0%. 
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There are differences in freezer temperatures and length of frozen time between the two 
studies. However, a previous study on 25(OH)D concentration in the CPP cohort reported no 
evidence of 25(OH)D degradation [175]. Long-term storage in 20◦C freezer will not cause a loss 
of 25(OH)D[176]; therefore storage differences between the two studies should not cause a 
significant difference in 25(OH)D concentration. 
3.3  GENETIC VARIANTS 
Candidate vitamin D pathway genes were selected from vitamin D literature and two 
recent GWAS [31, 32, 119, 123, 129, 141, 153, 159-161, 164-166, 177]. By focusing analysis on 
candidate genes, there is increased probability of finding associations. However, there is always 
a possibility of missing important variants in other genes. Potentially Functional SNPs within 
these candidate genes (GC, CYP27B1, and VDR) were selected for inclusion and additional 
tagging SNPs were identified using HapMap [178]. Using haplotype tagging minimizes 
redundancy data from the same haplotype block. Tagging SNPs were selected for CEU (Utah 
residents with ancestry from northern and western Europe) population first, and supplemented 
with additional tagging SNPs from ASW (Americans of African Ancestry in Southwest USA) 
population in order to represent the black and white populations in the two cohorts. By selecting 
the variants by race, there is less risk of excluding race/ethnic-specific variants. We specified for 
minor allele frequency (MAF) >10% since we are interested in common variants. In addition loci 
with a low MAF (<10%) have a significantly lower power to detect genotypic risk ratios than 
loci with higher MAF; therefore MAF <10% may result in false findings[179]. In total, 499 
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SNPs were selected: 128 markers for Genetic Ancestry, 39 for CYP27B1, 126 were for GC, and 
206 were for VDR. 
 Frozen serum from EVITA and CPP were thawed, cleaned, amplified, and genotyped 
using these selected SNPs. By genotyping both studies on each open array plate, the chance that 
any genotyping differences by study will be caused by genotyping error is reduced. Genotyping 
was conducted at the Graduate School of Public Health (University of Pittsburgh) using the 
QuantStudio 12K Flex platform. All SNPs were genotyped for every sample. Genotypes were 
analyzed using the TaqMan Genotyper software (version 1.3.1) and visual assessment of the data 
was used for confirmation. 
3.4  SAMPLE SIZE 
Aim 1 
Power estimates were calculated for preeclampsia and subtypes of preeclampsia (mild, 
severe, early-onset, and late-onset preeclampsia) in the EVITA cohort. STATA software[180] 
was used to estimate power for odds ratios=1.5, 1.8, 2, and 2.5 using the known sample sizes 
(Table 2). Since the outcome rate is low, the case-control approach can be used to estimate 
power[181]. Overall, power is > 80% to detect an association between 25(OH)D <25 nmol/L and 
overall preeclampsia, as well as late-onset, severe and mild forms of preeclampsia. We will not 
have power to report an association for early-onset preeclampsia. 
Aim 2 and 3 
For the genetic study, power was calculated using the total 3576 and 3111 samples for 
EVITA and CPP, respectively (Table 3). There was a control to case ratio of 4:1 and 2:1 for 
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whites and blacks in EVITA and 3.6:1 and 2:1 ratio for whites and blacks in CPP. Using Quanto 
version 1.2[182], power was calculated for each study by race for three inheritance modes: 
recessive, dominant, and log additive (Table 4). Calculations assumed loss of 20% of the 
individual samples and 10% of SNPs due to poor genotyping, sample quality, or failure of 
Hardy-Weinberg equilibrium. The calculations were based on allelic frequencies of 0.1, 0.2, and 
0.3. Due to multiple comparisons and the assumption that 10% of SNPs will fail, we used a p-
value of 0.00015 (p-value 0.05/340 SNPs). This is a conservative p-value for the calculations. 
Based on our assumptions, we will have power (>80%) to detect an odds ratio of 3 for whites 
and blacks in CPP and EVITA for variants with allele frequencies ≥ 0.1 and have either a log 
additive or a dominant mode of inheritance (Table 4). In addition, there is power to report an 
odds ratio of 2 for dominant and log additive modes of inheritance for CPP cohort (white and 
black) and EVITA (white). There is limited power to detect an association for recessive variants. 
3.5  CONFOUNDERS 
Potential confounder variables for EVITA and CPP are from the perinatal database and 
records from in-person interviews, respectively. Both sources provided maternal self-reported 
race/ethnicity, pre-pregnancy BMI (<18.5, 18.5-24.9, 25-29.9, >30), diabetes status(yes, no), 
education(<12 years, 12 years, and >12 years),  insurance (private, Medicaid), marital 
status(single, married), maternal age (<20, 20-29, >30), gestational age at delivery(continuous), 
parity, and season of blood draw (winter (December‒February), spring (March‒May), summer 
(June‒August), or fall (September‒November). Gestational age at delivery in CPP was based on 
the mother’s report of the first day of her last menstrual period. In comparison, gestational age at 
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delivery in EVITA was determined by best obstetric estimate comparing menstrual dating and 
ultrasound and was ascertained from the perinatal database. EVITA also contains additional 
information on provider type (hospital outpatient resident clinic, hospital-affiliated private 
practice). A composite socioeconomic status score was also available for CPP, which combines 
education, occupation, and family income data. 
ANALYSIS 
Aim 1 
In the EVITA case-cohort, a total of 950 pregnancies are missing maternal height (which 
is needed to calculate prepregnancy BMI) because the perinatal database did not collect height 
until 2003.  Women are also missing prepregnany weight (n=12), maternal education (n=379), 
diabetes (n=136), smoking (n=4), and parity (n=2).  We will use multiple imputation to address 
missing covariate data. The data will be imputed to create imputed datasets that assumes a 
multivariable normal distribution with a Markov Chain Monte Carlo approach[183, 184]. In this 
approach, missing values are filled in with simulated values. This is preferable to deleting 
samples with missing data which would cause loss of power. A disadvantage of this approach is 
the possibility of false values; however this is unlikely when missing is at random. We will 
impute the following log-transformed variables: prepregnany weight, height, diabetes status, 
smoking status (n=4 missing), education, and parity by including preeclampsia, 25(OH)D 
concentration, gestational age at blood draw, season and year of blood draw, batch number, 
maternal age, maternal race/ethnicity, type of insurance, provider type, marital status, gestational 
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age at delivery, and sample weight in the imputation model.  We will also run all analyses among 
women with complete data (n=1494). 
We will use multivariable log-binomial regression to calculate unadjusted and adjusted 
risk ratios and 95% confidence intervals for associations between maternal 25(OH)D and 
preeclampsia as well as its subtypes. Log-binomial regression assumes a binomial distribution of 
the outcomes. Cases are oversampled from the cohort; therefore we will include robust standard 
errors and weights[185]. The subjects will be weighted by the inverse of sampling probabilities. 
We will develop a parsimonious model[186] for overall preeclampsia by including all potential 
confounders (year of blood draw, batch, prepregnancy BMI, smoking status, gestational age of 
sample, insurance, parity, marriage status, maternal age, maternal race/ethnicity, maternal 
education, and season of blood draw) and removing variables whose exclusion from the model 
will not change the main exposure point estimate by at least 10%. A parsimonious model will 
reduce the risk of having an over-fit model which will hide the underlying model. We will 
include the same confounders for all preeclampsia subtype models. Mild preeclampsia cases will 
be excluded from the severe preeclampsia model. The same will be done for severe preeclampsia 
cases in the mild preeclampsia model, as well as early-onset cases in the late-onset preeclampsia 
model. In the models where 25(OH)D will be specified as restricted cubic spline terms, we will 
use linear combinations to calculate estimates of association for selected values of 25(OH)D 
concentrations relative to 25(OH)D = 75 nmol/L.  
In separate sensitivity analyses, we will exclude women with chronic hypertension or 
diabetes, as well as women with 25(OH)D >175 nmol/L. Women with these chronic conditions 
will be included in the original models. Chronic hypertension and diabetes may share a causal 
pathway with preeclampsia; therefore removing these mothers might hide the underlying 
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association. We will use the synergy index [187] to test for effect modification on the additive 
scale between vitamin D and race/ethnicity (Black vs. non-Black), parity (nulliparous vs. 
multiparity), and gestational age of blood sampling (< 15  vs. > 15 weeks gestation). Synergy 
index creates a ratio between combined effect and individual effects which tests for interaction 
on the additive scale versus the multiplicative scale. Assessing interaction in the additive scale 
may be more appropriate for biological interactions[188, 189]. 
Aims 2 And 3 
Quality Control 
Before analysis, multiple data-quality control steps must be performed for all genotype 
data using Plink software [190, 191]. First, we will assess genotype calling differences by plate 
to detect any problems in genotyping. If there are differences in call rates by plate, further 
investigation will assess if there was a laboratory error. 
Allelic frequencies can vary greatly between ancestral populations which may create 
spurious associations in gene association studies[192]. We will address this problem by using 
population stratification based on genetic ancestry using ancestry informative markers (AIMs) 
[193]. AIMs are superior to self-report since many people a composite of multiple ancestries.  
Individual ancestral proportions will be calculated using the Bayesian Markov chain Monte 
Carlo clustering algorithm [194-197] implemented in STRUCTURE 2.3 assuming K = 1 to 10. 
The number of subgroups will be determined by using an ad hoc statistic which is based on the 
rate change in the log probability of data between clusters (K) [198].  
Using the adjusted race data, we will split the data by study and ancestral cluster (K) for 
further quality control steps. We will assess data quality to remove any sub-standard markers and 
samples from subsequent association analysis. First, we will carefully scrutinize the distribution 
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of missing genotype rates by race, study, and between cases and controls to establish the most 
appropriate threshold. Typically, markers with a genotype call rate less than 95% are removed 
[199, 200]. There is a risk of including poor quality genotypes if this threshold is set too low. 
Extreme differential call rates between cases and controls may result in a bias. After removing 
poor quality markers, we will identify SNPs with a significant deviation form Hardy-Weinberg 
equilibrium (p-value >0.00001) [201]and remove of all markers with a very low minor allele 
frequency (<5%)[202]. These additional quality steps will identify extreme genotyping errors. It 
is important to assess HWE and MAF by race since some variants are ancestry-specific. Other 
quality control measures include creating scatter plots by race for controls only, by gene, and 
overall. We will consider including all variants with known functional effects. 
To determine population stratification, we will compare allele frequencies by race using 
Chi-square tests. If allele frequencies differ by race, and we ignore population stratification,  
there will be an increased chance of a false positive significance test[203]. We will divide the 
analysis for each study by race if there is evidence of population stratification. Another approach 
is to estimate ancestry and use this estimate in the models to remove the effect from the 
association test statistic[204, 205]. 
Analysis 
Analysis will follow a case-control design. Due to differences in the study populations, 
separate analyses will be conducted for CPP and EVITA and results will be combined together 
using meta-analysis. Depending on the model (preeclampsia versus 25(OH)D), the outcome will 
either be preeclampsia (0=no, 1=yes) or 25(OH)D concentration (continuous). We will also 
consider dichotomous 25(OH)D (≤ 25 nmol, ≤ 30 nmol/l, or ≤ 50 nmol/l). 
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Multiple inheritance patterns must be considered in our analysis. We will test for allelic 
(D allele versus d allele), dominant (DD+ Dd versus dd), recessive (DD versus Dd + dd), and 
genotypic (DD versus Dd versus dd) inheritance modes. To test whether there was a linear dose 
effect of the variant alleles (log-additive genetic model for trend test), variants will be coded as 
0, 1, and 2. This approach assumes additive risk while genotypic model does not provide any 
sense of ordering across the genotype. In addition, risk scores will be calculated where the score 
will be equal to the sum of the number of risk alleles across the SNPs [124]. This will allow us to 
determine if carriers of multiple risk variants have an increased risk of low 25(OH)D. In 
addition, we will determine mean 25(OH)D and preeclampsia incidence within each group of 
homozygous referent, heterozygous, and homozygous variant for each SNP. 
Parsimonious multivariable logistic regression model will be used for categorical 
outcomes and multivariable linear regression models for continuous outcomes. We will adjust 
for batch number (in EVITA only), year drawn, and 25(OH)D concentration (for preeclampsia 
models). Other possible covariates to include are gestational age at blood draw, season of blood 
draw, prepregnancy BMI, mother’s age, parity, smoking status, insurance, mother’s education, 
and site. Covariates will be selected using 10 % change-in-estimate rule[206]. We will compare 
R2, log-likelihood, AIC, BIC to help find best fit model. In addition, interactions will be 
examined in preeclampsia models to assess if there is effect modification of 25(OH)D 
concentration in the preeclampsia models.  
Due to the large number of SNPs, it is important to adjust for multiple testing. Failure to 
adjust may produce excessive false positives or true positives may be overlooked. A conservative 
method to consider is the Bonferroni method (p-value/# of SNPs). If SNPs are in linkage 
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disequilibrium, other less conservative methods are to be considered including Holm, Sidak or 
FDR [207-209]. 
Past literature on variants in GC and VDR genes have found several common haplotypes 
affect disease risk. Haplotype structure will be determined by using the method of Gabriel and 
colleagues[210]. Each haplotype will be tested in the regression model in comparison with all 
other haplotypes. 
To combine studies, we will use fixed- and random-effects meta-analysis to calculate 
effect size for each variant weighted by study size[211]. Composite odd ratios will be calculated 
by weighting individual odd ratios by the inverse of their variance. For a more balanced weight 
for each study, a random effects model will be used since it assumes that there is a distribution of 
true effect sizes rather than one true effect. We will use the Higginś test (I2) to calculate 
heterozygosity which measures the degree of inconsistency in the results of the studies[212].  
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Table 9. Power calculations by mode of inheritance and allele frequency for EVITA and CPP by 
maternal race. 
Mode of inheritance 
Recessive  Dominant Log additive 
EVITA Odds Ratio  2 
  Allele frequency: 
   0.1 
   0.2 

























Odds Ratio 3 
  Allele frequency: 
   0.1 
   0.2 

























CPP Odds Ratio 2 
  Allele frequency: 
   0.1 
   0.2 
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4 . LOW MATERNAL 25-HYDROXYVITAMIN D CONCENTRATION 
INCREASES THE RISK OF SEVERE AND MILD PREECLAMPSIA 
4.0  ABSTRACT
Objective: The objective of this case-cohort study was to evaluate the relationship between 
maternal 25-hydroxyvitamin D (25(OH)D) concentration and preeclampsia overall and by 
severity. 
Methods: From an eligible cohort of 12,861 women who had serum banked from aneuploidy 
screening, we randomly sampled a subcohort of 2327 pregnancies and all remaining 
preeclampsia cases (n=650 cases). Preeclampsia (defined as new-onset hypertension and 
proteinuria) and its mild and severe forms were identified using ICD-9 codes. Maternal serum 
collected at ≤20 weeks gestation was measured for 25(OH)D. We used log-binomial regression 
with restricted cubic splines to estimate the association between 25(OH)D and preeclampsia after 
adjusting for confounders. 
Results: Approximately 21% of the randomly-selected sample had 25(OH)D <50 nmol/L. We 
found that the adjusted risk of preeclampsia declined as serum 25(OH)D increased to 50 nmol/L, 
and then plateaued (test of non-linearity p<0.05). The adjusted preeclampsia risk ratios (95% 
confidence intervals) for 25(OH)D at <25 nmol/L, 25-≤50 nmol/L, and 50-≤ 75 nmol/L were 2.4 
(1.2, 4.8), 1.9 (0.68, 1.7), and 1.2 (0.87, 1.7), respectively, compared with those with 25(OH)D 
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≥75 nmol/L. Similar dose-response associations were observed with severe and mild 
preeclampsia. 
Conclusion: Randomized trials of vitamin D supplements are needed to test the causality of this 
association. 
Keywords: Pregnancy; Preeclampsia; Hypertension; Vitamin D deficiency; 25-Hydroxyvitamin 
D 
List of abbreviations and acronyms 
25(OH)D, maternal 25-hydroxyvitamin D; BMI, body-mass index; ICD-9, International 
Classification of Diseases; RR, Risk ratio; CI, confidence interval; S, Synergy Index 
4.1  INTRODUCTION 
Preeclampsia is a pregnancy-specific, multi-systemic condition that is defined by new-
onset hypertension and either proteinuria or end-organ dysfunction at 20 weeks of gestation or 
later. Complicating 3‒5% of pregnancies in the U.S.[91, 213], preeclampsia is a leading cause of 
maternal and infant morbidity and mortality [214]. The origins of preeclampsia likely lie in 
abnormal placental development, which induces oxidative stress and maternal systemic 
inflammation that lead to the clinical symptoms seen in preeclampsia [215, 216]. 
Vitamin D may play a role in the etiology of preeclampsia by regulating the transcription 
and function of genes associated with placental function, including placental invasion, normal 
implantation, and angiogenesis [38, 217]. Vitamin D also modulates immune function and 
inflammatory response [39]. Many [17, 18, 102, 103, 218-223] but not all [224-226] 
observational studies suggest vitamin D deficiency before disease onset is a risk factor for 
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preeclampsia. Some of the uncertainty in the literature may be because preeclampsia has not 
been studied separately by subtype [227, 228]. Classifying preeclampsia cases into more 
homogenous subgroups based on severity may enhance our understanding of specific exposures 
in the pathogenesis of preeclampsia[229]. Our objective was to evaluate the relationship between 
maternal 25-hydroxyvitamin D (25(OH)D) concentration at ≤20 weeks gestation and the risk of 
preeclampsia and subtypes based on symptom severity. 
4.2  METHODS 
EVITA is a case-cohort study of vitamin D and adverse pregnancy outcomes that was 
approved by our institution review board. The study has been described in detail previously 
[230]. Briefly, EVITA used data and banked serum samples from women who had aneuploidy 
screening at ≤20 weeks gestation and who subsequently delivered at Magee-Womens Hospital of 
UPMC in Pittsburgh, Pennsylvania. We merged clinical data from a perinatal database with a 
database of all screened samples to identify a cohort of 12,861 eligible pregnancies. We 
randomly selected 2327 of these pregnancies, and augmented this subcohort with all remaining 
preeclampsia cases (n=650 total cases). 
Preeclampsia was defined as new-onset hypertension and proteinuria for the first time 
after 20 weeks gestation on the basis of International Classification of Diseases-9 codes (ICD-9) 
(642.4-642.6). Mild preeclampsia without mention of preexisting hypertension was identified 
(ICD-9 code 642.4). Severe preeclampsia was defined as severe preeclampsia or eclampsia with 
no pre-existing hypertension (ICD-9 codes 642.5-642.6). Maternal aneuploidy screening samples 
drawn at ≤20 weeks gestation were used because this time period generally precedes the clinical 
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onset of preeclampsia. Samples were stored at -80°C for up to 12 years. Serum was assayed for 
total 25-hydroxyvitamin D (25(OH)D) (25(OH)D2+25(OH)D3) using liquid chromatography–
tandem mass-spectrometry [172]. We categorized serum 25(OH)D concentration as <25 nmol/L, 
25 to <50 nmol/L, 50 to <75 nmol/L, and ≥75 nmol/L[173]. To model flexible non-linear 
relations between 25(OH)D and preeclampsia, we used restricted cubic splines with three knots 
[174, 231, 232]. 
The perinatal database provided information on potential confounders: maternal self-
reported race/ethnicity, prepregnancy body mass index (BMI) [self-reported weight (kg) divided 
by height (m2)], prepregnancy diabetes, education, marital status, smoking, insurance, provider 
type, parity, and season of blood draw. 
We used multiple imputation to address missing data on height (n=950 missing, because 
the perinatal database did not collect height data until 2003), prepregnancy weight (n=12), 
education (n=379), diabetes (n=136), smoking (n=4), or parity (n=2). The data were imputed to 
create 22 imputed datasets that assumed a multivariable normal distribution with a Markov 
Chain Monte Carlo approach [183, 184]. The number of imputed datasets was based on variance 
and unrestricted fraction of missing information [233]. A previous publication detailing the 
multiple imputation methods has been described elsewhere [230]. 
We used multivariable log-binomial regression to calculate risk ratios (RR) and 95% 
confidence intervals (CI) for associations between maternal 25(OH)D and preeclampsia as well 
as its subtypes. Cases were oversampled from the cohort; therefore, we used robust standard 
errors [185]. Subjects in the subcohort were weighted by the inverse of their sampling 
probability. We developed a parsimonious model by removing potential confounders from a full 
model if their exclusion did not change the main exposure point estimate by ≥10%. Only year at 
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blood drawn, batch number, and gestational age of sample collection met our definition of 
confounding. We included race/ethnicity, parity, smoking status, prepregnancy BMI, and season 
out of convention. We used the synergy index (S) [187] to test for effect modification on the 
additive scale by race/ethnicity, parity, and gestational age of blood sampling. 
4.3  RESULTS 
The subcohort was predominately non-Hispanic white, college graduates, married, 
normal weight, nulliparous, non-smokers, and had private health insurance (Table 10). 
Compared with the subcohort, preeclampsia cases were older, and more likely to be Black, 
nulliparous, and recipients of Medicaid. They also completed fewer years of education and had a 
higher prepregnancy BMI. When separated into mild and severe preeclampsia cases, a greater 
proportion of severe cases were Black, >30 years of age, obese, unmarried, recipients of 
Medicaid, chronic hypertensives and multiparous as compared with mild cases. 
The geometric mean 25(OH)D was 64.6 (95% CI 64.4, 64.8) nmol/L in the subcohort and 
57.8 (95% CI 57.3, 58.3) nmol/L among the cases. In the subcohort, 3.3%, 18.0%, 36.8%, and 
41.9% of women had 25(OH)D concentration <25 nmol/L, 25 to < 50 nmol/L, 50 to < 75 
nmol/L, and ≥ 75 nmol/L, respectively. The weighted incidence of preeclampsia in the cohort 
was 5.0%. The unadjusted weighted incidence of preeclampsia was 9.1%, 5.8%, 5.4%, 3.9% 
among women with 25(OH)D <25, 25 to <50, 50 to <75, and ≥75 nmol/L, respectively. 
After adjusting for confounders, there was a dose-response association between maternal 
vitamin D status and the risk of preeclampsia (Figure 1). As serum 25(OH)D concentration 
increased, preeclampsia risk declined, then plateaued at approximately 50 nmol/L. Relative to 
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25(OH)D of 75 nmol/L, women with 25(OH)D of 20, 30, or 40 nmol/L had 2.3-, 1.7-, and 1.3-
fold increases in risk of preeclampsia, respectively (Table 11). After excluding women with 
prepregnancy hypertension or diabetes, the associations were attenuated. Adjusted RR (95% CI) 
for 25(OH)D of 20, 30, or 40 nmol/L were 1.9 (1.0, 3.5), 1.5 (0.99, 2.3), and 1.2 (0.94, 1.6) 
compared with 75 nmol/L. Similar results were found in the categorical analysis (Table 12). For 
example, after confounder adjustment, there was a 2.4-fold increased risk of preeclampsia for 
women with 25(OH)D <25 nmol/L compared to those with 25(OH)D >75 nmol/L. 
The weighted incidences of severe and mild preeclampsia were 1.5% and 3.5%, 
respectively, and the incidence of each subtype increased as 25(OH)D category increased (Table 
12). Confounder-adjusted associations between categories of 25(OH)D and risk of severe and 
mild preeclampsia were similar to results observed for overall preeclampsia. The dose-response 
associations indicating high risk with low 25(OH)D and a plateau at approximately 50 nmol/L 
were also similar for mild and severe disease (Appendix Figures 1-2). 
None of these results varied by race/ethnicity [S=8.5, p=0.897], parity [S=3.4, p=0.249], 
or gestational age of blood draw [S=17, p=0.102]. 
4.4 DISCUSSION 
In this large contemporary cohort of pregnancies electing aneuploidy screening, we 
observed a dose-response association between maternal 25(OH)D at ≤20 weeks of gestation and 
risk of preeclampsia. Risk declined sharply from 20 to 40 nmol/L, and then plateaued at 50 
nmol/L. We observed similar findings when preeclampsia cases were separated into severe and 
mild subtypes. Association remained after adjusting for confounders. 
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Our results are consistent with four meta-analyses of observational studies [17, 18, 234, 
235] despite individual observational studies having mixed results. All four meta-analyses 
revealed women with 25(OH)D < 50 nmol/L in pregnancy experienced an increased risk of 
preeclampsia compared to women with 25(OH)D ≥75nmol/L, with pooled odds ratios ranging 
from 1.6 to 2.3 [17, 18, 234, 235]. Our observation of a threshold at 50 nmol/L 25(OH)D 
supports these findings. However, the numbers of women with 25(OH)D <37.5 or <25 nmol/L 
were too small for these meta-analyses to report meaningful estimates that we could compare 
with ours. 
Past literature also reported that low 25(OH)D was associated with increased risk of 
severe preeclampsia [15, 20, 24, 105, 236]. In one of the largest studies of maternal 25(OH)D 
and preeclampsia (n=560 mild and n=157 severe cases), investigators observed mothers with 
25(OH)D ≥ 50 nmol/L at ≤ 26 weeks gestation had a 40% reduction in severe preeclampsia risk 
compared with those with 25(OH)D <50 nmol/L (RR 0.65 95% CI 0.43, 0.98) after adjusting for 
confounders [15]. Contrary to our findings, they found no association for mild preeclampsia, 
perhaps due to differences in case definition, age of serum samples, or in population 
characteristics. All other studies only examined severe forms of preeclampsia [24, 105, 236]. 
Our results suggest that vitamin D deficiency may impact pathophysiologic changes 
found in both severe and mild subtypes of preeclampsia, including an inappropriate 
inflammatory response, endothelial dysfunction, and high blood pressure [237]. The active form 
of vitamin D has a role in maintaining an appropriate inflammatory response in the maternal-
fetal interface [97]. Endothelial function is maintained via vitamin D by improving proliferation, 
migration and tubule formation [238, 239]. Furthermore, there is evidence that vitamin D 
metabolites protect endothelial cells from oxidative stress and minimize the effects of exposure 
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to preeclampsia-related factors [240, 241]. In addition, active vitamin D influences the renin-
angiotensin-aldosterone system, including the regulation of blood pressure [40]. 
Our reliance on correct assignment of ICD-9 codes for preeclampsia may contribute to 
some misclassification. Since preeclampsia might manifest before proteinuria is induced, 
clinicians may be categorizing potential preeclamptic cases as gestational hypertension. 
Therefore, experts at American Congress of Obstetricians and Gynecologists recommend 
gestational hypertension and preeclampsia be classified with preeclampsia with or without severe 
characteristics [242]. We were unable to test the relationship between 25(OH)D and gestational 
hypertension since our perinatal database used ICD-9 codes which lack this detailed information. 
Women who elect prenatal aneuploidy screening may be different than those who do not 
elect screening. However, we have previously demonstrated that there are no major differences 
in the eligible EVITA subcohort compared with the full cohort [230]. As with any observational 
study, there is potential for unmeasured confounding; lack of data on socioeconomic status, 
physical activity, or genetics may have biased our results. Our study population may have limited 
generalizability to more diverse populations. In addition, our case-cohort contained few women 
with 25(OH)D <25 nmol/L which led to imprecise estimates. We also did not have other 
biomarkers of vitamin D, such as the vitamin D binding protein (VDBP), which controls the 
bioavailability of free 25(OH)D [22]. 
Major strengths of this study were the large number of preeclamptic cases and our ability 
phenotype preeclampsia based on severity. In addition, we used serum samples collected before 
onset of symptoms, which is important to establish temporality. Lastly, we were able to 
successfully confirm findings from meta-analyses and reviews in overall preeclampsia and 
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severity subtypes. These findings further develop our understanding of the role of vitamin D in 
preeclampsia. 
If others confirm our findings of a threshold effect for preeclampsia at approximately 
25(OH)D of 50 nmol/L, these results have important implications. The Institute of Medicine 
recommendation of achieving 25(OH)D <50 nmol/L to reduce skeletal outcomes may be enough 
to prevent preeclampsia. This may imply low doses of vitamin D supplementation are required to 
reduce preeclampsia risk. 
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Figure 1. Risk of preeclampsia with increasing 25(OH)D concentration (nmol/L) using restricted 
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5. VARIATION OF CYP27B1, GC, AND VDR GENES AND PREECLAMPSIA RISK 
USING TWO MULTI-ETHNIC PREGNANCY COHORTS 
5.0  ABSTRACT
Objective: The objective of this candidate gene association study was to evaluate the relationship 
between maternal genetic variation of 3 vitamin D metabolism genes and preeclampsia risk. 
Methods: Using two pregnancy cohorts, we studied 471 Black and 546 White preeclampsia cases 
and 1160 Black and 2059 White controls. For every sample, we genotyped 39 CYP27B1 
(Chromosome (chr.)12), 126 GC (chr. 4), and 206 VDR (chr.12) tagging SNPs. Using 
multivariable logistic regression models, we estimated the association between SNPs and 
preeclampsia risk using the allelic approach. Meta-analyses were conducted to calculate 
estimates of association between and within case-control studies. 
Results: After adjusting for multiple comparisons, only trends of associations were observed for 
GC and VDR SNPs. For Black mother, those who carried the minor allele for three SNPs 
(rs11732451 [GC], rs4340112 [VDR], rs10459217 [VDR]) had 3.8-, 7.7-, and 8.4-fold increased 
odds of preeclampsia. In contrast, the odds of preeclampsia was 80-75% lowered for Black 
mothers who carried the minor allele for 3 SNPs (rs1099028 [GC], rs757344 [VDR], rs12721364 
[VDR]). No CYP27B1 variant was associated with preeclampsia risk. In the meta-analysis, two 
VDR intron variants (rs886441 and rs2853561) were associated with a decreased odds of 
64 
preeclampsia for all Black mothers. We did not observe any trends for White mothers in the 
meta-analysis. 
Conclusion: Our research observed possible trends of association between several GC and VDR 
SNPs and preeclampsia risk. If these findings are replicated in only Black mothers, the effect of 
genetic variation on vitamin D and preeclampsia in observational studies may be minimized by 
controlling for race/ethnicity. 
5.1  INTRODUCTION 
Preeclampsia is a pregnancy-specific, multi-systemic condition that complicates 3-5% of 
all pregnancies [171, 243]. It is defined by new-onset hypertension and proteinuria, and/or any 
signs or symptoms of end-organ dysfunction (renal insufficiency, impaired liver function, 
pulmonary edema, thrombocytopenia) at 20 weeks of gestation or later [242]. In addition to 
contributing to 18% of maternal mortality in the United States [244], preeclampsia is one of the 
leading causes of maternal morbidity [245] and infant mortality and morbidity [91], and its 
complications are more likely to affect Black than White women [246]. Etiology of preeclampsia 
is thought to involve defective invasion of extravillous trophoblasts, which causes a failure in 
maternal spiral artery remodeling and impairment in blood flow [215]. This abnormal 
placentation leads to oxidative stress [216] and eventually maternal systemic inflammatory 
response and maternal symptoms. 
Vitamin D may have an important role in the development of preeclampsia. Vitamin D 
regulates the transcription and function of genes associated with placental invasion and normal 
implantation [38, 217] and modulates the activities of antioxidant enzymes, inflammatory 
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response, and hypertension [40, 238]. Observational studies on vitamin D deficiency and 
preeclampsia risk have produced mixed results [17, 222]. Some of this heterogeneity in findings 
may be explained by a genetic effect or gene-environment interaction. 
Vitamin D from sunlight, foods, or supplements is transported by chylomicrons and the 
vitamin D binding protein (DBP, encoded by GC gene) to the liver [29, 48, 49]. Enzyme-driven 
hydroxylating reactions convert vitamin D to 25(OH)D (25-hydroxyvitamin D) [29]. 25(OH)D is 
further hydroxylated by 1 alpha-hydroxylase (encoded by CYP27B1) to produce the active form 
of vitamin D, 1,25(OH)2D (1,25-dihydroxyvitamin D) [27]. 1,25(OH)2D attaches to the vitamin 
D receptor (VDR) expressed in target organs and cells [54]. The GC, CYP27B1, and VDR genes 
are integral to vitamin D metabolism and comprise of common variations that may increase risk 
of preeclampsia. Our objective was to determine the associations between allelic sequence 
variation in GC, CYP27B1, and VDR genes and preeclampsia risk. 
5.2  METHODS 
This candidate gene association study used existing data and stored blood samples from 
two pregnancy populations have been described in detail previously, the Collaborative Perinatal 
Project (CPP) and EVITA [227, 230]. CPP enrolled more than 55,000 women at 12 U.S medical 
centers from 1959-1965 [247]. From the subsample of 28,429 women with singleton 
pregnancies, with no preexisting conditions (pregestational diabetes, hypertension, or 
cardiovascular disease) and a banked serum sample at <26 weeks, we selected all preeclampsia 
cases (n=173 White, n=283 Black) and 2986 randomly-selected non-preeclamptic controls 
among Black or White women. 
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EVITA studied 12,861 women with singleton pregnancies who had an available banked 
serum from aneuploidy screening at ≤20 weeks and subsequent delivery at Magee-Womens 
Hospital of UPMC in Pittsburgh, Pennsylvania. From this sample, we selected all preeclampsia 
cases (n=313 White, n=173 Black) and 2327 randomly-selected non-preeclamptic controls also 
among Black and White women. 
Preeclampsia was defined in the CPP as gestational hypertension and proteinuria for the 
first time after 20 weeks, and return of abnormalities to normal in the postpartum period. 
Gestational hypertension was classified based on two or more measurements of systolic blood 
pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg. Proteinuria was determined 
by two random urine dipsticks of 1+ protein or one dipstick of 2+ protein which were tested for 
albumin every 8 weeks. At each visit, medical and obstetric events were recorded and random 
urine samples were tested for albumin. A validation study showed a high degree of accuracy 
between blood pressure and urinary albumin and original medical records [248]. In EVITA, 
preeclampsia was defined by ICD-9 codes of 642.4-642.6). 
We selected three candidate pathway genes (GC, CYP27B1, and VDR) from vitamin D 
literature [31, 119, 122, 124, 126-135]. For each gene, functional candidate SNPs were selected 
and then augmented with additional tagging SNPs using HapMap phase 3 data [178]. Tagging 
SNPs were selected for the CEU (Utah residents with ancestry from northern and western 
Europe) population first after specifying minor allele frequency >10% and 50 kilobases up and 
down stream of the gene. This SNP selection was then supplemented with additional tagging 
SNPs from the ASW (Americans of African Ancestry in Southwest USA) population in order to 
represent the Black and White populations in the two case-control studies. In total, 499 SNPs 
were selected: 39 for CYP27B1, 126 for GC, 206 for VDR, and 128 markers for genetic ancestry. 
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Serum for CPP and EVITA were frozen for 50 and 12 years, respectively. Serum was 
thawed and cleaned using Qiagen kits (QIAGEN, Valencia, CA) to reduce contaminants and 
inhibitors. We used REPLi-g midi kit (QIAGEN, Valencia, CA) to amplify the resulting product. 
QuantStudio 12K Flex platform (Life Technologies, Carlsbad, CA) was used to genotype after 
amplification for the selected SNPs. All SNPs were genotyped for every sample. Genotypes were 
analyzed using the TaqMan Genotyper software (Version 1.3.1, Grand Island, NY) and visual 
assessment of the data was used for confirmation. All plates included controls and 10% of 
samples were genotyped in duplicate as internal controls. 
Potential confounding variables came from the perinatal database in EVITA and in-
person interviews for CPP. Gestational age was based on best obstetric estimate comparing 
menstrual dating and ultrasound estimates was used in EVITA and on the mother’s report of the 
first day of her last menstrual period in CPP (ultrasound was not available in the 1960s). Both 
studies included data on pre-pregnancy BMI (<18.5, 18.5-24.9, 25-29.9, >30), preexisting 
diabetes (yes, no), maternal education (<12 years, 12 years, and >12 years), marital status 
(single, married), maternal age (<20, 20-29, >30), parity, and season of blood draw (winter 
(December‒February), spring (March‒May), summer (June‒August), or fall (September‒
November)). Data on provider type (hospital outpatient resident clinic, hospital-affiliated private 
practice) were available for women in EVITA. A composite socioeconomic status score was 
available for CPP, which combines education, occupation, and family income data [247]. 
Statistical methods 
Multiple data-quality control steps were performed for all genotype data using PLINK 
software (Version 1.07, Boston, MA) [190, 191] (Figure 1). Samples and markers with sample 
genotyping call rate or marker genotyping call rate <50% were omitted. All SNPs included in the 
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analysis had call rate >50%, MAF >0.05 and were in Hardy–Weinberg equilibrium (P>0.00001). 
Beagle software (Version 4.0, Seattle, WA) was used to impute missing genotypes for SNPs and 
samples that passed the quality control measures[249]. Missing calls with >0.85 r2 were replaced 
by imputed calls for further analysis (9.7% of CPP Black mothers, 13% of CPP White mothers, 
8.4% EVITA White mothers, and 11% EVITA Black mothers). 
Population stratification to categorize mothers as Black or White was based on genetic 
ancestry and self-reported race [193]. First, individual ancestral proportions were calculated and 
implemented in STRUCTURE 2.3 (Stanford, CA) assuming K = 1 to 4 [194-197]. The number 
of subgroups (K=2) was determined by using an ad hoc statistic based on the rate change in the 
log probability of data between clusters (K) [198]. Using this approach, each individual was 
assigned into one of two ancestral groups—White or Black—the genetic ancestral probability of 
belonging to CEU or ASW was >85%, respectively. Race was based on self-report when the 
probability was <85%. 
Separate analyses were conducted by case-control study (CPP or EVITA) and race (Black 
or White). Allelic frequencies (carriers of minor allele versus major allele) by cases status were 
assessed for each SNP using a chi-square test. SNPs were further examined in univariate logistic 
regression models to estimate preeclampsia odds ratios (OR) and 95% confidence intervals 
(95%CI) using the allelic approach (minor allele vs. major allele). We first modeled functional 
SNPs in parsimonious models by removing potential confounders from the model if their 
exclusion did not change the main exposure point estimate by ≥10%. By using this method, we 
adjusted for batch number (in EVITA only), year drawn (in EVITA only), site (CPP), season of 
blood draw, and mother’s age. Other variables did not change the estimate. Season of blood draw 
and mother’s age met our definition of confounding in all models. In EVITA models, we also 
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included batch number and year, and in CPP models, we additionally included study site. For 
consistency, we included the same covariates for the tagging SNP models. 
We used random-effects meta-analysis to summarize race-specific beta coefficients 
across the two studies by weighting individual coefficients by the inverse of their variance. The 
Higgins test (I2) was used to calculate heterogeneity as a measure of inconsistencies in the results 
of the studies. 
RESULTS 
After quality control steps, the analysis included 992 preeclampsia cases (506 CPP, 486 EVITA), 
and 3,161 controls (1619 CPP, 1542 EVITA). The basic characteristics of CPP and EVITA 
studies are presented in Tables 12 and 13. The mean age of CPP was 24 (+/- 5.6) years and of 
EVITA was 29 (+/- 6.3) years. Compared to Black controls in CPP, Black cases completed less 
years of education, smoked less, and had higher prepregnancy BMI. The same differences were 
observed for White controls and cases. Compared to Black controls in EVITA, Black cases were 
more likely to be nulliparous and non-smokers, and more likely to have completed less years of 
education and have higher prepregnancy BMI. There were similar differences for White mothers 
in EVITA, except there was no significant difference in smoking status. 
For both studies and maternal race, geometric means of 25(OH)D were lower for cases 
compared with controls (Table 14). Additionally, despite case-status and study, Black mothers 
had lower geometric mean of 25(OH)D compared with White mothers. 
Black mothers from EVITA had the most gene coverage with 44, 39, and 36% of each 
CYP27B1, GC SNPs, and VDR SNPs successfully passing all quality control steps (Figure 1). 
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For White mothers in EVITA, 10, 8, and 6% of each CYP27B1, GC, and VDR SNPs passed the 
same quality measures. Black mothers in CPP also had lower genotype coverage, with 5 % of 
CYP27B1, 5% of GC, and 4% VDR SNPs passing quality control, while 3% of CYP27B1, 12% 
of GC and 9% of VDR SNPs passed for White mothers. 
Using only SNPs that passed quality control steps, preeclampsia risk differed by allelic 
frequency for 1 CYP27B1 SNP, 3 GC SNPs and 3 VDR SNPs (Table 15). In Black mothers in 
EVITA, the minor alleles of rs238522 (CYP27B1) and rs16847105 (GC) were 30% and 15% 
more commonly carried by controls than cases, respectively. Also in Black mothers from 
EVITA, the GC SNP rs843010 and VDR SNP rs7975232 minor allele were 29-47% more likely 
carried by cases compared with controls, while the minor alleles of two VDR SNPs (rs10459217 
and rs1544410) were 21-26% more likely carried by controls than cases. Lastly, for White 
mothers in CPP, the minor allele of GC SNP rs1526692 was 18% more likely carried by cases 
compared with controls. 
After adjusting for confounders, we observed associations between 11 SNPs (5 GC SNPs 
and 6 VDR SNPs) and preeclampsia risk (Table 16). Further adjusting for multiple comparisons 
and linkage disequilibrium, no SNP remained statistically significant; however 2 GC SNPs 
(rs11732451 and rs1099028) and 4 VDR SNPs (rs757344, rs12721364, rs4340112, and 
rs10459217) had trends of associations with preeclampsia risk (p<0.01) for only Black mothers 
in EVITA. Compared with major allele carriers of rs11732451 for Black mothers in EVITA, 
those who carried the minor allele had 3.6-fold increased odds of preeclampsia. In contrast, the 
odds of preeclampsia was 75% lower for minor allele carriers of rs1099028 (intron variant) 
compared with major allele carriers. Adjusted odds ratios and 95% confidence intervals for 
minor allele carriers of 4 VDR SNPs (rs757344 (intron), rs12721364, rs4340112, rs10459217) 
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were 0.24 (0.10, 0.60), 0.20 (0.06, 0.65), 7.7 (1.6, 36), and 8.4 (1.9, 37) compared with major 
allele carriers, respectively. No CYP27B1 variant was associated with preeclampsia risk. 
Only three functional variants successfully passed quality control steps. Minor allele 
carriers of missense mutations in CYP27B1 (rs2229103) (OR 0.79 95%CI 0.45, 1.4; p=0.42), 
VDR (rs11574115) (OR 1.4 95%CI 0.28, 7.1; p=0.68), and in the GC gene (rs4588) (OR 0.65 
95%CI 0.26, 1.6; p=0.340) were not associated with preeclampsia risk. 
A meta-analysis was conducted to summarize associations by race/ethnicity between CPP 
and EVITA, as well as to summarize associations between Black and White mothers. In the 
meta-analysis, we identified two VDR intron variants (rs886441 and rs2853561) with trends of 
decreased odds of preeclampsia for Black mothers in CPP and EVITA (Figure 2). There was a 
reduced odds of preeclampsia for minor allele carriers of rs886441 (Meta OR 0.53 95% CI 0.73, 
1.0; p=0.05) and rs2853561 (OR 0.76 95%CI 0.58, 0.99 p=0.043). There were no significant 
differences in the estimates by study (I2 0% p=0.34; I2 0% p=0.89). 
5.4  DISCUSSION 
In a study of two racially diverse populations, there were trends towards association for 
Black mothers in those who carried minor alleles of 2 GC and 4 VDR SNPs with preeclampsia 
risk. By using the meta-analysis approach, we identified two other VDR variants with trends of 
associations for all Black mothers. However, the analysis could not detect associations for White 
mothers, perhaps due to gene coverage differences. Due to the lack of statistical significance, it is 
not possible to make conclusions without improving our sample size and gene coverage. 
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Our study has the largest gene coverage compared with other gene association studies on 
preeclampsia risk. Studies relating allelic variation in vitamin D metabolizing genes and 
preeclampsia risk are sparse. In a cohort study of 164 preeclamptics, 154 gestational diabetics, 
and 213 pregnant women without either condition, there were no differences in three VDR SNPs 
by maternal genotype, allelic, and haplotype frequencies [43]. However, limiting the genotyping 
to three SNPs may have missed functional variants important to the development of poor 
pregnancy outcomes. In a Chinese population, minor allele carriers of rs1544410 SNP were more 
likely to develop preeclampsia (OR=1.41, 95% CI 1.11–1.61) [250]. Our study did not observe 
an association with the same SNP for Black mothers from EVITA (OR=0.64 95%CI 0.23, 1.8), 
perhaps due to differences in ancestral backgrounds. 
Genetic variations in these two vitamin D metabolizing genes may impact maternal 
25(OH)D concentrations through several mechanisms. Past studies of non-pregnant adults 
observed common variations in GC gene modulate DBP levels and affect affinity of DBP to 
25(OH)D [116]. Poor GC-25(OH)D binding may reduce the 25(OH)D concentration and other 
vitamin D metabolites in serum [117]. Adequate 25(OH)D and 1,25(OH)2D are important for 
mounting an appropriate inflammatory response in the maternal-fetal interface[97], maintaining 
endothelial function[238], and protecting endothelial cells from oxidative stress and minimizing 
the effects of exposure to preeclampsia-related factors[240, 241]. 
Genetic variation in VDR may impact the activity of VDR, increasing a mother’s 
susceptibility to preeclampsia. Variations in the VDR gene may enhance or reduce expression or 
binding activity of VDR [118] and even determine its own expression[251]. Several cell culture 
studies have observed possible functions of VDR that may influence the development of 
preeclampsia, including maintaining an inflammatory response [97] and endothelial repair [238]. 
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There is also evidence from cell culture that, through a VDR-mediated mechanism,1,25(OH)2D3 
suppresses renin transcription, which is important in the regulation of blood pressure [40]. 
Our study observed 2 intron variants in GC gene and 6 tagging SNPs in VDR may be 
associated with preeclampsia risk, while there was no evidence of associations for functional 
SNPs. These intron SNPs and tagging SNPs may be in LD with functional variants that increase 
risk of preeclampsia, or the associations may have occurred by chance. However, we took 
measures to increase our ability of finding true associations by controlling for multiple 
comparisons. Additionally, minor allele carriers of these SNPs increased or decreased risk of 
preeclampsia in Black mothers which may be causing some of the heterogeneity observed in 
observational studies. However, these trends may have only occurred in Black mothers due to the 
lower genotyping rates for samples from White mothers. 
We had a limited ability to conduct meta-analyses within racial/ethnic groups as well as 
between the two studies due to genotyping coverage differences between these groups. Our study 
had a large number of samples that failed quality control steps, therefore we could not adequately 
compare associations by race/ethnicity. For the same reasons, our analysis was limited to the 
allelic approach. DBP protein controls the bioavailability of free 25(OH)D[22], therefore DBP 
may be a better predictor of preeclampsia. However, we genotyped common SNPs in the GC 
gene that encodes DBP which may be serving as a proxy for DBP protein levels. Additionally, 
there may be unmeasured confounders between CPP and EVITA study populations that would 
reduce our ability to compare results; yet by using the meta-analysis approach, we were able to 
combine results despite this limitation. There are some unmeasured confounders to consider, 
including vitamin D supplement-use, diet, and sun exposure, which may have led to biased 
results. Instead, we controlled for season of blood draw to minimize the effect of vitamin D 
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exposure differences. The relationship between SNPs and preeclampsia risk may depend on 
25(OH)D concentration; however, we were limited in power to test this interaction. Past 
literature on variants in GC and VDR genes have found several common haplotypes affect 
disease risk; however we did not have the statistical power to address this analysis. Our findings 
are not generalizable to other racial groups due to differences in allelic frequencies by 
race/ethnicity. 
Our study had several strengths, including a large sample of racially diverse pregnant 
women consisting of a large number of preeclamptic cases. Our use of two pregnancy 
populations in the genetic analysis improved our power for detecting associations. All of our 
subjects were genotyped for ancestral markers, therefore we did not rely on self-reported race. 
Since many variants are ancestral-specific, this strategy decreased spurious associations. In 
addition, by using a tagging SNP approach, we reduced redundancy while improving our 
statistical power for detecting associations. 
Our study observed several GC and VDR SNPs may be associated with preeclampsia risk. 
Avoiding genetic variability between individuals in observational studies may cause an 
underestimation or overestimation in the association between 25(OH)D and preeclampsia risk. If 
associations are ancestry specific, stratifying or controlling by race may decrease the effect of 
genetics in observational studies. However, a replication study is needed to confirm these 
findings in another racially diverse pregnancy population. 
75 
Ancestry Informative Markers 
 CPP: 
  127 self-reported White changed to Black 
  92 self-reported Black changed to White 
 EVITA:  
  165 self-reported White changed to Black 
  42 self-reported Black changed to White 
Pre-quality control dataset 
 CPP      Black: 1329 
 CPP      White: 1370 
 EVITA Black:    657 
 EVITA White: 1654 
Marker genotyping 
call rate  
(Keep <60%) 
CPP Black: 340  
CPP White: 339  
EVITA Black: 340 
EVITA White: 340 
Sample genotyping call rate 
(Keep <50%) 
CPP Black: 1070 
CPP White: 1128 
EVITA Black: 551 
EVITA White: 1477 
Minor allele 
frequency 
(Keep > 5.0%) 
CPP Black: 310  
CPP White: 292  
EVITA Black: 316 




CPP Black: 60 
CPP White: 43  
EVITA Black: 147 
EVITA White: 36 
SNP Imputation 
(Keep >85%) 
CPP Black: 9.7%  
CPP White: 13%  
EVITA Black: 11%  
EVITA White: 8.4% 
Final Number of SNPs 
CPP Black: 2 CYP27B1, 6 GC, 8 VDR 
CPP White: 1 CYP27B1, 15 GC, 18 VDR 
EVITA Black: 16 CYP27B1, 49 GC, 75 VDR 
EVITA White: 4 CYP27B1, 10 GC, 13 VDR 
Final Sample size (n) 
CPP Black: 1051 
CPP White: 1074 
EVITA Black: 551 
EVITA White: 1477 
Figure 2. Quality control measures for EVITA and CPP 
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Figure 3. Meta-analysis between and with EVITA and CPP. Covariate adjusted (site (CPP), 
batch (EVITA), year drawn (EVITA), BMI, mother’s age, and season of blood draw) OR and 
95% CI. 
0.1 1 10
rs886441:Black, EVITA: OR 0.48
95%CI (0.19, 1.2)
rs886441: Black, CPP: OR 0.77
95%CI (0.56, 1.1)
rs886441:Meta OR 0.73 95%CI
(0.53, 1.0)
rs2853561 White, CPP: OE 0.74
95%CI (0.49,1.1)
rs2853561 Black, EVITA: OR 0.64
(0.26, 1.6)
rs2853561 Meta: OR 0.76 (0.58,
0.99)
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Table 12: Population characteristics for controls and cases in CPP by race and preeclampsia 
status.  
CPP: Black cases 
n=288  
Number (%) 
CPP: Black controls 
n=782 
Number (%) 
CPP: White cases 
n=233 
Number (%) 




 <25 nmol/L 
 25-50 nmol/L 








































  <18.5 
   18.5-24.9 
   25-29.9 


































































* P-value <0.05 for t-test
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Table 13. Population characteristics for controls and cases in EVITA by maternal race and 


















 <25 nmol/L 
 25-50 nmol/L 
 50-75 nmol/L 
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 Some high school 
 High school 








































P-value <0.05 for t-test 
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Table 14. Geometric means and 95% confidence intervals of 25-hydroxvitamin D by study, 
maternal race, and case-status. 
Study Maternal race Geometric Mean (95%CI) 
Cases 
Geometric Mean (95%CI) 
Controls 
EVITA Black 44 (43, 45) nmol/L 50 (49, 50) nmol/L 
White 69 (68,70) nmol/L 72 (72,72) nmol/L 
CPP Black 44 (43,45) nmol/L 50 (49, 50) nmol/L 
White 51 (50, 51) nmol/L 52 (52, 53) nmol/L 
Table 15. Allelic frequency for SNPs in CYP27B1, GC, and VDR by preeclampsia case-status 
and maternal race in CPP and EVITA. 
allele frequency by allele 
(1 or 2) 
and case status 
Cases Controls 





1 2 1 2 p-value 
CYP27B1 Black EVITA rs238522 C/T 155/333 0.73 0.27 0.61 0.39 <0.01* 
GC Black CPP rs16847105 T/A 243/662 0.72 0.28 0.67 0.33 0.04* 
rs843010 C/T 154/333 0.85 0.15 0.92 0.08 <0.01* 
White CPP rs1526692 C/A 196/424 0.67 0.33 0.73 0.27 0.02* 
VDR Black EVITA rs10459217 A/C 134/289 0.78 0.22 0.72 0.28 0.04* 
rs1544410 G/A 143/313 0.66 0.34 0.57 0.43 0.01* 
rs7975232 C/T 137/282 0.76 0.24 0.83 0.17 0.02* 
*p-value<0.05
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Table 16. Association between selected CYP27B1, GC, and VDR single nucleotide polymorphisms and the risk of preeclampsia by 
maternal race and study. 
Gene Race Study SNP OR (95%CI) p-value Adj OR1 p-value 
CYP27B1 
Black EVITA rs238522 C/T 0.58 (0.39,0.85) 0.01* 0.18 (0.03, 1.1) 0.06 
GC 
Black CPP rs16847105 T/A 0.74 (0.55,1.0) 0.05 0.84 (0.61,1.1) 0.27 
 rs842881 CT 0.70 (0.49,0.98) 0.04 0.73 (0.51,1.0) 0.08 
EVITA rs60696209 G/C 0.66 (0.45,0.98) 0.04 1.0 (0.39,2.6) 0.97 
rs842881 AG 0.70(0.44,1.1) 0.12 0.32 (0.11,0.96) 0.04 
rs11732451 AG 1.4 (0.92,2.0) 0.13 3.8 (1.6,9.5) 0.00* 
rs1099028 AG 0.94 (0.55,1.6) 0.81 0.20 (0.06,0.61) 0.01* 
rs843010 C/T 1.7 (1.1,2.8) 0.03 0.80 (0.32,2.0) 0.64 
White CPP rs1526692 C/T 1.4 (1.0,1.9) 0.04 1.5 (1.1,2.1) 0.02 
VDR 
Black EVITA rs757344 AG 0.68 (0.45,1.0) 0.07 0.24 (0.10,0.60) <0.01* 
rs12721364 C/T 0.86 (0.54,1.4) 0.54 0.19 (0.06,0.66) <0.01* 
rs4340112 C/T 1.1 (0.64,1.9) 0.73 7.7 (1.6,36) 0.01* 
: rs10459217 A/C 1.2 (0.61,2.2) 0.65 8.4 (1.9,37) <0.01* 
rs11168319 GA 0.57(0.36,0.91) 0.02 0.48 (0.13,1.8) 0.28 
rs1544410 GA 0.65 (0.43,0.98) 0.04 0.64 (0.23,1.8)) 0.37 
rs7975232 C/T 1.7(1.1,2.7) 0.01 1.5 (0.52,4.3) 0.46 
 CPP rs11835083 C/G 0.69 (0.48,0.99) 0.04 0.75 (0.51,1.1) 0.13 
White EVITA rs2544037 AG 0.86 (0.65,1.1) 0.30 0.62 (0.39,0.99) 0.04 
* P<0.01
1 Adjusted for maternal age, site (CPP only), season of blood draw, year of blood draw (EVITA only), and batch (EVITA only) 
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6. VARIATION IN CYP27B1, GC, VDR GENES AND VITAMIN D STATUS IN TWO 
MULTI-ETHNIC PREGNANCY COHORTS. 
6.0  ABSTRACT
Objective: The objective of this candidate gene association study was to evaluate the relationship 
between maternal genetic variation in 3 vitamin D metabolism genes and 25-hydroxyvitamin D 
concentration. 
Methods: From two pregnancy cohorts, we genotyped 39 CYP27B1 [chromosome (Chr.) 12] 
single nucleotide polymorphisms (SNPs), 126 GC (Chr.4) SNPs, and 206 VDR (Chr.12) SNPs. 
These cohorts consisted of 768 Black and 851 White pregnant mothers in the Collaborative 
Perinatal Project and 378 Black and 1164 White pregnant mothers in the EVITA cohort. 
Maternal serum collected at ≤26 weeks gestation was measured for 25(OH)D. We used 
multivariable linear regression to estimate the association between genotype and log-transformed 
25(OH)D after adjusting for confounders. Meta-analyses were conducted to calculate estimates 
of association for minor allele genotype carriers compared with major allele carriers between and 
within cohorts. 
Results: Approximately 28 and 54% of each cohort had 25(OH)D <50 nmol/L. For Black 
mothers in EVITA only, compared with major allele genotypes, minor allele genotypes of 
rs1844885 (GC) and rs11168275 (VDR) had 32-51% increases in 25(OH)D and those of 
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rs11732451 (GC) had a 23% decrease in 25(OH)D on average after controlling for multiple 
comparisons and adjusting for multiple comparisons. For all Black mothers, there was a 
significant increase in 25(OH)D for rs1844885 and a trend of decreased 25(OH)D for CYP27B1 
rs10877016 SNP. Within EVITA, the meta-analysis observed trends of decreased 25(OH)D (GC: 
rs962227) and increased 25(OH)D (VDR: rs2238135). 
Conclusions: Our findings support a role for common genetic variants in the regulation of 
maternal serum 25(OH)D concentration. A replication study using a multi-ethnic pregnancy 
population is needed to confirm these findings. 
6.1  INTRODUCTION 
One in four pregnant women in the U.S. has suboptimal vitamin D status [73-75], as 
defined by serum 25-hydroxyvitamin D (25(OH)D) concentrations <50 nmol/L [252]. Non-
Hispanic Black women are 3-5 times as likely as non-Hispanic White women to be deficient in 
vitamin D [70, 253]. The widespread deficiency and racial/ethnic gap in its prevalence is 
concerning because of the association between low 25(OH)D and the increase risk of offspring 
rickets [254], preterm birth [255], preeclampsia [18], small-for-gestational age birth [234], 
childhood asthma [256], and type 1 diabetes mellitus [257]. Understanding factors that influence 
vitamin D status and whether they differ by maternal race/ethnicity is of major public health 
importance. 
Single nucleotide polymorphisms (SNPs) in several key genes in the vitamin D metabolic 
pathway may partially determine 25(OH)D status [124]. Vitamin D binding protein [DBP, 
encoded by the vitamin D-binding (GC) gene] is critical for transporting vitamin D in serum to 
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the liver [29, 48, 49], where it is hydroxylated to 25(OH)D [29]. Allelic variants in the GC gene 
modulate DBP levels and affinity for 25(OH)D [116]. After 25(OH)D is returned to circulation, 
it is further hydroxylated by 1 alpha-hydroxylase (encoded by CYP27B1 also known as 
cytochrome p450 27B1) to the active form of vitamin D, 1,25(OH)2D (1,25-dihydroxyvitamin 
D), in the kidney and other cells and organs in the body [27]. 1,25(OH)2D attaches to the vitamin 
D receptor (VDR) expressed in target organs and cells to perform genomic roles [54]. SNPs in 
CYP27B1 and VDR influence serum 25(OH)D by changing the rate at which 25(OH)D is 
hydroxylated [143] either directly or through VDR triggering a negative feedback loop. 
While there have been many studies exploring the contribution of genetic variation in 
vitamin D status among non-pregnant adults separately by race/ethnicity [31, 124, 258], there is 
a paucity of data among pregnant women. Pregnancy is accompanied by important alterations in 
vitamin D metabolism, including increasing circulation of DBP[259], enhanced hydroxylation of 
25(OH)D to 1,25(OH)2D in kidneys and other cells and organs in the human body[260], and 
transportation of 25(OH)D into the placenta [58]. Our objective was to evaluate the relationship 
between common genotypes in GC, CYP27B1, and VDR genes and maternal 25(OH)D 
concentrations in two large pregnancy cohorts of Black and White mothers. 
6.2  METHODS 
We used data and samples from two pregnancy cohort studies on vitamin D and adverse 
birth outcomes that were approved by the University of Pittsburgh Institutional Review Board 
and have been described in detail elsewhere [227, 230]. The Collaborative Perinatal Project 
(CPP) enrolled >55,000 women at 12 U.S medical centers in 1959-65. The cohort of eligible 
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women for the parent study included women with singleton pregnancies, no preexisting 
conditions, and a banked serum sample at < 26 weeks (n= 28,429). We then randomly selected a 
subcohort of 2986 eligible women for 25(OH)D assay. From this group, we selected 1370 White 
and 1329 Black women with non-preeclamptic term deliveries for the present analysis. 
EVITA studied an eligible cohort of 12,861 singleton pregnancies receiving aneuploidy 
screening at <20 weeks gestation and subsequent delivery at Magee-Womens Hospital of UPMC 
in Pittsburgh, Pennsylvania. A subcohort of 2327 eligible women were selected for 25(OH)D 
assessment, and from this group we chose all term pregnancies without preeclampsia of non-
Hispanic White (n=1654) and non-Hispanic Black (n=657) women. In both cohorts, racial/ethnic 
groups other than White and Black were excluded from genotyping because of small samples. 
Maternal serum samples in CPP were collected at ≤26 weeks of gestation and stored for 
40 years at −20°C with no recorded thaws. EVITA samples were collected at <20 weeks of 
gestation and were stored at -80°C for 2 to 12 years. Sera from both cohorts were sent to the 
same Vitamin D External Quality Assessment Scheme certified laboratory. Samples were 
assayed for total 25-hydroxyvitamin D (25(OH)D) [25(OH)D2 + 25(OH)D3] using liquid-
chromatography-tandem mass spectrometry based on National Institute of Standards and 
Technology (NIST) standards[172]. Intra- and the inter-assay variations were ≤9.6% and 
≤10.9%, respectively. We defined vitamin D deficiency as 25(OH)D < 50 nmol/L[252]. 
We selected functional candidate SNPs from three candidate pathway genes (CYP27B1, 
GC, VDR) using vitamin D literature and 2 genome-wide association studies [31, 119, 122, 124, 
126-135]. In addition, we included tagging SNPs using HapMap phase 3 data [178].Tagging 
SNPs were first selected from Utah residents with ancestry from northern and western Europe 
(CEU) population and then supplemented with additional tagging SNPs from Americans of 
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African Ancestry in Southwest USA (ASW). We specified SNPs with a minor allele frequency 
>10% and 50 kilobases up- and downstream of each gene. In total, 499 SNPs were selected: 39 
for CYP27B1, 126 for GC, 206 for VDR, and 128 markers for genetic ancestry. 
Before amplifying and genotyping the DNA, serum was thawed and cleaned using 
Qiagen kits (QIAGEN, Valencia, CA) to reduce impurities. The REPLi-g midi kit (QIAGEN, 
Valencia, CA) was then used for whole genome amplification. After amplification, all SNPs 
were genotyped for every sample using QuantStudio 12K Flex platform (Life Technologies, 
Carlsbad, CA). The quality of the genotype calls were analyzed using the TaqMan Genotyper 
software (Version 1.3.1, Grand Island, NY) and was confirmed by visual assessment of the data. 
Gestational age in EVITA was based on best obstetric estimate, while in CPP it was 
based on the mother’s report of the first day of her last menstrual period. Maternal self-report 
and medical records were used to ascertain pre-pregnancy body-mass index (BMI) (<18.5, 18.5-
24.9, 25-29.9, >30), preexisting diabetes status (yes, no), marital status (single, married), 
maternal age (<20, 20-29, >30), parity, and season of blood draw [winter (December‒February), 
spring (March‒May), summer (June‒August), or fall (September‒November)]. Data on provider 
type (hospital outpatient resident clinic, hospital-affiliated private practice), maternal education 
(<12 years, 12 years, and >12 years), and insurance (private and Medicaid) were available for the 
EVITA cohort. A composite socioeconomic status (SES) score, which combines education, 
occupation, and family income data [247], was available for CPP. 
Statistical methods 
Genetic ancestry was calculated and implemented using STRUCTURE 2.3 (Stanford, 
CA) assuming K = 1 to 4 [194-197]. The number of subgroups (K=2) was determined by using 
an ad hoc statistic based on the rate change in the log probability of data between clusters (K) 
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[198]. Using this genetic ancestry approach, each study sample was classified as coming from a 
White or Black mother. If the probability of belonging to CEU or ASW was <85%, samples were 
assigned to self-reported race. 
Samples with a genotyping call rate <50% were omitted from further quality control 
steps. All SNPs included in the analysis had call rates >50%, minor allele frequency (MAF) 
>0.05 and were in Hardy–Weinberg equilibrium (P>0.0001). These data-quality control steps 
were performed using PLINK software (Version 1.07, Boston, MA) [190, 191] (Figure 1). 
Beagle software (Version 4.0, Seattle, WA) [249] was used on the remaining data after these 
quality control steps. The software was used for conducting multiple imputations on missing 
genotype data to create probabilities of genotypes (AA, AB, and BB). Data with an imputation 
probability of >0.85 replaced the missing data, while the remaining data (≤ 0.85) remained 
missing. 
Using Stata software (version 12.1, College Station, Texas), we also used multiple 
imputation to address missing covariate data for EVITA [height (n=645 missing, because the 
perinatal database for EVITA did not collect height data until 2003), prepregnancy weight 
(n=10), education (n=265), diabetes (n=95), and smoking (n=4)] and CPP [BMI (n=137), SES 
(n=47), diabetes (n=7), smoking (n=13), and parity (n=3)]. The data were imputed separately by 
study and race to create 10 imputed datasets each that assumed a multivariable normal 
distribution with a Markov Chain Monte Carlo approach [183, 184]. A previous publication 
detailing the multiple imputation methods has been described elsewhere [230]. 
Analyses were stratified by cohort (CPP and EVITA) and race/ethnicity (Black or 
White). For each cohort and racial group, we calculated the geometric mean of 25(OH)D 
(nmol/L) by genotype and tested for differences using nonparametric trend tests. SNPs 
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associated with 25(OH)D concentration were further examined in multivariable linear regression 
models. 25(OH)D was log-transformed to reduce skewness of the data. These models were used 
to estimate associations between 25(OH)D and genotype. Genotype of the major allele was set as 
the reference genotype (AA, AB, BB) for each SNP. We first modeled functional SNPs in 
parsimonious models by removing potential confounders from the model if their exclusion did 
not change the main exposure point estimate by ≥10%. We adjusted for batch number (in EVITA 
only), year drawn (in EVITA only), site (CPP), season of blood draw, and mother’s age. Other 
variables did not change the estimate >10% (education, insurance, smoking status, diabetes 
status, and parity). For comparability, we used the same model for tagging SNPs. All 
associations were adjusted for multiple comparisons and linkage disequilibrium (LD). LD of two 
SNPs characterizes dependent heritability which was measured using PLINK software. 
We used random-effects meta-analysis to summarize race-specific beta coefficients 
across the two studies by weighting individual coefficients by the inverse of their variance [211]. 
The Higginś test (I2) was used to calculate heterogeneity to measure the degree of inconsistency 
in the results of the studies[212]. 
6.3  RESULTS 
Based on ancestral informative markers, we reclassified the racial group of 8.1% and 
9.0% of women in CPP and EVITA, respectively (Figure 1). Of the 4226 samples that passed 
QC steps, up to 13% of the genotyped data was imputed. After imputation, 1065 preeclampsia 
and preterm birth cases were excluded, resulting in a total of 1619 women in CPP and 1542 
women in EVITA. 
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Compared with Black mothers in EVITA, greater proportions of Black mothers in CPP 
completed more years of education, smoked, had a lower prepregnancy BMI, and were 
nulliparous (Table 17). Similarly, compared with White mothers in EVITA, White mothers in 
CPP had a lower prepregnancy BMI, and a higher proportion of smokers and nulliparity. Unlike 
Black mothers, White mothers in CPP completed less years of education compared with White 
mothers in EVITA. In addition, the prevalence of women with 25(OH)D <50 nmol/L was higher 
in Black mothers of CPP than EVITA (78% vs 47%) and higher in White mothers of CPP 
compared with White mothers in EVITA (43% vs 10%). The geometric means and 95% 
confidence intervals of 25(OH)D in Black mothers in CPP and EVITA were 44 nmol/L (43, 45 
nmol/L) and 66 nmol/L (64, 67 nmol/L), respectively. These means and 95%CI of 25(OH)D in 
White mothers in CPP and EVITA were 52 nmol/L (50, 53 nmol/L) and 71 nmol/L (70, 76 
nmol/L), respectively. 
The highest success genotyping rate was in Black mothers of EVITA, with 33% of 
CYP27B1, 24% of GC, and 21% of VDR SNPs successfully genotyped (Figure 1). The success 
rate was lower for White mothers in EVITA with 8% of CYP27B1, 6% of GC, and 5% of VDR 
SNPs genotyped. Overall, few SNPs passed quality control steps in CPP. For each CYP27B1, 
GC, and VDR SNPs, 5 % passed for Black mothers, while 3% of CYP27B1, 8% of GC and 8% of 
VDR SNPs passed for White mothers. 
The test of trend for 25(OH)D concentration by genotype (AA, AB, BB) was significant 
(p<0.05) for two CYP27B1 SNPs (rs10877016 and rs10877012), one GC SNP (rs11732451), and 
4 VDR SNPs (rs11168261, rs11168275, rs7974708, and rs2238135) (Table 18). Compared with 
the univariate results, associations were slightly attenuated after adjusting for season of blood 
draw, mother’s age, BMI, site (for CPP), batch (for EVITA), and year drawn (for EVITA) (Table 
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19). After adjusting for multiple comparisons and linkage disequilibrium, only estimates for 2 
GC SNPs (rs1844885, rs11732451) and 1VDR SNP (rs11168275) remained statistically 
significant for only Black mothers in EVITA. Mothers who carried the minor allele genotypes of 
these SNPs had 32-51% increases (rs1844885, rs11168275) or a 23% decrease (rs11732451) in 
25(OH)D concentration compared with carriers of major allele genotypes. Heterozygous carriers 
for 4 SNPs were also associated with trends of lowered (rs11732451) and increased (rs7974708, 
rs2238135, rs11168275) 25(OH)D concentrations. Only one functional SNP passed quality 
control steps: a missense mutation in CYP27B1 (rs2229103). In EVITA, White women with the 
minor allele genotype were not associated with a significant change in 25(OH)D (beta=-0.13 
95%CI 0.33, 0.06; p=0.17). 
Using a meta-analysis, we summarized associations within all Black mothers and all 
White mothers, as well as between cohorts. Only GC SNP rs1844885 SNP had a significant 
association with 25(OH)D in the meta-analysis after adjusting for multiple comparisons (Meta-
beta 0.27 95%CI 0.14, 0.40; p<0.00001) with no significant variation between studies (I2=0% 
p=0.454). The meta-analysis on CYP27B1 SNP rs10877016 for White mothers in EVITA and 
CPP observed a trend of decreased 25(OH)D (Meta beta -16, 95%CI -25, -5.9 p= 0.003; I2 =0% 
p=0.680). Further meta-analyses on 2 SNPs between Black and White mothers only in EVITA 
also had trends of associations with no significant variation between race/ethnicities (GC SNP 
rs962227, meta-beta -0.17, 95%CI -0.297, -0.043 p=0.009; I2 0% p=0.444, VDR SNP rs2238135 
minor allele carriers meta-beta 0.10 95%CI 0.02, 0.18 p= 0.028 I2=0.0% p=0.632).  
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DISCUSSION 
Using two large and racially diverse pregnancy cohorts, we observed allelic variation of genes 
with roles in vitamin D transport (GC), hydroxylation (CYP27B1) and gene regulation (VDR) 
were associated with 25(OH)D concentration in pregnant women who delivered to term. If these 
findings are confirmed in a replication study, our findings support a role for common genetic 
variants in the regulation of maternal circulating 25(OH)D concentration in pregnancy. 
To our knowledge, ours is the most complete candidate gene analysis of vitamin D in 
pregnant women to date. Two previous candidate gene association studies have analyzed the 
relationship between maternal 25(OH)D concentration and maternal genetic variation of 
CYP27B1 and VDR genes [42, 177], while ours is the first to have analyzed maternal SNPs in the 
GC gene. Using a cohort of 222 pregnant White women with gestational diabetes, researchers 
observed the minor allele genotype of rs10877012 was more common in women with 25(OH)D 
> 50 nmol/L at 24 weeks of gestation compared with the major allele genotype (p=0.01) [177]. 
This is the only analyzed CYP27B1 SNP in the study and they did not adjust for covariates. Our 
study only observed a trend of increased 25(OH)D for the same SNP (beta=0.06 95% CI 0.00, 
0.13; p=0.046) for White mothers of EVITA. In a separate study of 354 White pregnant women, 
maternal 25(OH)D did not vary by VDR genotype. The study included 4 SNPs, none of which 
were included in our analysis. However, their study was limited by small sample size for the 
minor alleles (n=1 to 2) [42]. 
Genetic variations in these three vitamin D metabolizing genes may impact maternal 
25(OH)D concentrations through several mechanisms. Variations in the CYP27B1 gene may 
influence serum 25(OH)D and 1,25(OH)2D concentrations by changing the rate of hydroxylation 
[143]. Common genetic variations in GC gene are associated with varying 25(OH)D levels, DBP 
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levels, and DBP affinity for 25(OH)D [116]. DBP protein controls the bioavailability of free 
25(OH)D [22], therefore DBP levels may be a predictor of 25(OH)D concentration. We 
genotyped common SNPs in the GC gene that encode DBP, which may be serving as a proxy for 
DBP protein levels. Additionally, studies suggest 25(OH)D concentrations may be limited via 
activated VDR by downregulating 25(OH)D hydroxylation and the formation of 25(OH)D [261]. 
Our study observed the minor allele genotype for intron variants and tagging SNPs were 
associated with 25(OH)D concentration. These SNPs may be in LD with functional variants that, 
in turn, reduce 25(OH)D concentration. 
There are several important limitations to consider in our study. We had a limited ability 
to conduct meta-analyses within racial/ethnic groups as well as between cohorts due to 
genotyping coverage differences between groups. Our study had a large number of samples that 
failed quality control steps. Therefore, we could not adequately compare associations by 
race/ethnicity. There may be unmeasured confounders that differ between CPP and EVITA study 
populations; however, by using the meta-analysis approach, we were able to combine results 
despite this limitation. Our study could not determine causality between genetic variation and 
25(OH)D concentration. Instead, it is possible that the associations we observed may be due to 
shared factors. We were also limited from conducting gene-gene interaction and haplotype 
analyses. Lastly, due to differences in allelic frequencies by race/ethnicity, our findings might 
not be generalizable to other racial groups. 
Our study has several strengths, including a large sample of racially diverse pregnant 
women. All of our subjects were genotyped for ancestral markers. Therefore, we did not rely on 
self-reported race. Since many variants are ancestral-specific, this strategy will decrease spurious 
associations in our genetic analysis. Circulating 25(OH)D concentrations were measured using 
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the gold standard approach at one laboratory, in as few batches and in as short a time frame as 
possible, thus attenuating any potential technical errors of measurement. In addition, by using 
tagging SNP approach, we reduced redundancy while improving our statistical power for 
detecting associations. 
Maternal 25(OH)D concentration is largely dependent on the sun exposure and diet [60], 
but our research observed genetic differences may also be contributing. The rate at which 
vitamin D is metabolized may differ by genotype after controlling for confounders. Therefore, to 
improve maternal vitamin D status in pregnancy, vitamin D supplementation may need to 
consider variability due to genetic variation in vitamin D metabolism genes. However, these 
findings need to be replicated in a different pregnancy study before making these conclusions. 
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Ancestry Informative Markers 
 CPP: 
  127 self-reported White changed to Black 
    92 self-reported Black changed to White 
 EVITA:  
  165 self-reported White changed to Black 
    42 self-reported Black changed to White 
Pre-QC dataset 
 CPP      Black: 1329 
 CPP      White: 1370 
 EVITA Black:    657 
 EVITA White: 1654 
Marker genotyping 
call rate  
(Keep <60%) 
CPP Black: 340  
CPP White: 339  
EVITA Black: 340 
EVITA White: 340 
Sample genotyping 
call rate  
(Keep <50%) 
CPP Black: 1070 
CPP White: 1128 
EVITA Black: 551 
EVITA White: 1477 
Minor allele 
frequency 
(Keep > 5.0%) 
CPP Black: 310  
CPP White: 292  
EVITA Black: 316 




CPP Black: 60 
CPP White: 43  
EVITA Black: 147 
EVITA White: 36 
SNP Imputation 
(Keep >85%) 
CPP Black: 9.7%  
CPP White: 13%  
EVITA Black: 11%  
EVITA White: 8.4% 
Total SNPs for analysis 
CPP Black: 2 CYP27B1, 6 GC, 11 VDR 
CPP White: 1 CYP27B1, 10 GC, 16 VDR 
EVITA Black: 13 CYP27B1, 30 GC, 44 
VDR 
EVITA White: 3 CYP27B1, 7 GC, 11 
VDR 
Final Sample size 
(Exclude preeclampsia 
cases and preterm birth 
cases)  (n) 
CPP Black: 768 
CPP White: 851 
EVITA Black: 378 
EVITA White: 1164 
Figure 4. Quality control measures for EVITA and CPP. 
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Figure 5. Meta-analysis between and within EVITA and CPP. Covariate adjusted (site (CPP), batch (EVITA), year drawn (EVITA), 
BMI, and season of blood draw) and 95%CI. 
-50 -30 -10 10 30 50
rs1844885: Black, EVITA + 34, 95%CI (16,
55)
rs1844885: Black, CPP + 19, 95%CI(-10,
58)
rs1844885: Meta + 31, 95%CI (15, 59)
rs10877016: White, EVITA -18, 95%CI (-
30, -4.9)
rs10877016: White, CPP  -14, 95%CI (-28,
3.0)
rs10877016: Meta -16, 95%CI (-25, -5.9)
rs962227: Black, EVITA -20, 95%CI(-33, -4)
rs962227: White, EVITA -11 (-26, 6)
rs962227: Meta -16, 95%CI (-26, -4.2)
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Table 17. Descriptive characteristics of CPP and EVITA by maternal race. 

















25(OH)D ( nmol/L) 










































  <18.5 
   18.5-24.9 
   25-29.9 


















   Less than high 
school 
   High school 
   Some college 







































* p<0.05 for t-test comparing White and Black mothers between each cohort.
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Table 18. Single nucleotide polymorphisms with significant differences in mean 25-hydroxy 
vitamin D by genotype. 
SNP Maternal race Study SNP 
Genotype 
n mean(nmol/L) Minor allele 
frequency 







49 (47, 53) 
48 (43, 53) 
68 (56, 83) 
10% 







72 (71, 74) 
71 (68, 74) 
58 (49, 70) 
12% 







71 (69, 73) 
71 (69, 74) 
77 (73, 82) 
27% 







49 (46, 52) 
47 (42, 53) 
68 (59, 80) 
15% 







58 (53, 62) 
45 (41, 49) 
43 (38, 48) 
34% 







51 (47, 54) 
46 (41, 52) 
43 (36, 52) 
21% 







53 (49, 57) 
49 (45, 53) 
40 (34, 46) 
30% 







46 (44, 49) 
59 (53, 65) 
79 (65, 94) 
11% 







70 (68, 72) 
75 (73, 78) 
74 (68, 80) 
17% 







70 (68, 72) 
75 (72, 77) 
79 (73, 86) 
22% 
*p-value< 0.05, test of trend
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Table 19. Selected CYP27B1, GC, and VDR SNPs: unadjusted and adjusted coefficients and 
95%CI for maternal log-25(OH)D1. 
Gene Race/ 
ethnicity 













-0.04 (-0.16, 0.08) 
0.32 (0.16, 0.49) 
0.53 
<0.001          
ref 









-0.01 (-0.06, 0.04) 















-0.04 (-0.17, 0.08) 
 0.33 (0.18, 0.48) 
0.49 
<0.001    
ref 
-0.02 (-0.13, 0.09) 
0.28   (0.14,0.41) 
0.74 
<0.001*        








<0.001         
ref 
-0.18 (-0.29,-0.08) 
-0.26 (-0.40, -0.12) 
<0.001 
<0.001*         













<0.001          





0.24    (0.13, 0.36* 
0.52    (0.35,0.69) 
<0.001 





<0.001*      





0.08 (0.03, 0.12) 




0.06 (0.02, 0.11) 
0.04 (-0.04,0.12) 
<0.001* 
0.35         










0.05   (0.01, 0.10) 
0.12   (0.03,0.20) 
0.09 
0.01          
*significant p-values after adjusting for multiple comparisons and linkage disequilibrium
1 No associations in CPP were significant after adjusting for multiple imputations and 
linkage disequilibrium.  
2 Adjusted for maternal age, BMI, year of blood draw, and batch 
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7.  SYNTHESIS 
7.0  OVERVIEW OF RESEARCH FINDINGS
This dissertation used data from two pregnancy cohorts to study the relationship between 
25(OH)D and preeclampsia risk, and the associations of each 25(OH)D concentration and 
preeclampsia risk with maternal genetic variation of three vitamin D metabolizing genes (GC, 
CYP27B1, and VDR). Our research observed 25(OH)D <50 nmol/L increased risk of 
preeclampsia, as well as mild and severe forms of preeclampsia. In the candidate gene 
association studies, we observed trends of associations between SNPs of GC and VDR and risk 
of preeclampsia. Additionally, we observed allelic variations of GC, CYP27B1, and VDR were 
associated with 25(OH)D concentration in pregnant women who delivered to term. The 
following summarizes our findings for this dissertation. 
1. Determine the effect of vitamin D deficiency on risk of preeclampsia.
We used a randomly sampled subcohort of 2327 pregnancies and all remaining 
preeclampsia cases (n=650 cases) from EVITA. The association between 25(OH)D and 
preeclampsia was estimated by using log-binomial regression with restricted cubic splines. 
Adjusting for confounders, risk declined sharply from 20 to 40 nmol/L, and then plateaued at 50 
nmol/L (test of non-linearity p<0.05). Similar dose-response associations were observed with 
severe and mild preeclampsia. The adjusted preeclampsia risk ratios (95% confidence intervals) 
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for 25(OH)D at <25 nmol/L, 25-≤50 nmol/L, and 50-≤ 75 nmol/L were 2.4 (1.2, 4.8), 1.9 (0.68, 
1.7), and 1.2 (0.87, 1.7), respectively, compared with those with 25(OH)D ≥75 nmol/L. Our 
results are consistent with four meta-analyses of observational studies [17, 18, 234, 235], and 
with past literature on low 25(OH)D and  severe preeclampsia[15, 20, 24, 105, 236]. Contrary to 
a previous study, we observed an association for mild preeclampsia[15]. 
2. Determine the relationship between maternal genetic variation in GC, CYP27B1, and
VDR on risk of preeclampsia. 
Using a candidate gene approach, we studied 283 Black and 223 White preeclampsia 
cases, as well as 768 Black and 851 White controls from CPP. From EVITA, we used 173 Black 
and 313 White cases, and 378 Black and 1164 White controls. We genotyped 39 CYP27B1, 126 
GC, and 206 VDR tagging SNPs for every sample. Using multivariable logistic regression 
models, we estimated the association between SNPs and preeclampsia risk using the allelic 
approach. Meta-analyses were conducted to calculate estimates of association for minor allele 
carriers compared with major allele carriers between and within cohorts. In summary, only 
trends of association were observed in this study. Black mothers in EVITA who carried the 
minor alleles for three SNPs (rs11732451 [GC], rs4340112 [VDR], rs10459217 [VDR]) had 3.8-, 
7.7-, and 8.4-fold increased odds of preeclampsia. In contrast, the odds of preeclampsia was 80-
75% lowered for mothers who carried the minor alleles for 3 SNPs (rs1099028 [GC], rs757344 
[VDR], rs12721364 [VDR]). No CYP27B1 variant was associated with preeclampsia risk. In the 
meta-analysis, two VDR intron variants (rs886441 and rs2853561) were associated with 
decreased odds of preeclampsia for all Black mothers (CPP and EVITA). We did not observe 
any trends for White mothers in the meta-analysis. 
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In summary, our study observed 2 intron variants in GC and 6 tagging SNPs in VDR may 
be associated with preeclampsia risk. Due to the lack of statistical significance, it is not possible 
to make conclusions without improving our sample size and gene coverage. Significant 
associations between SNPs and preeclampsia risk would support evidence of a genetic influence 
in the relationship between vitamin D and preeclampsia risk. 
3. Determine the effect of GC, CYP27B1, and VDR gene on vitamin D deficiency.
From CPP and EVITA, we genotyped 39 CYP27B1, 126 GC, and 206 VDR SNPs using 
the tagging SNP approach. These cohorts consisted of 768 Black and 851 White pregnant 
mothers in CPP and 378 Black and 1164 White pregnant mothers in the EVITA cohort. After 
excluding preterm and preeclampsia cases from the analysis, we used multivariable linear 
regression to estimate the association between genotype and log-transformed 25(OH)D after 
adjusting for confounders. Meta-analyses were conducted to calculate estimates of association 
for minor allele genotype carriers compared with major allele carriers between and within 
cohorts. Compared with major allele genotypes, Black women in EVITA with minor allele 
genotypes of rs1844885 (GC) and rs11168275 (VDR) had 32-51% increases in 25(OH)D and 
those of rs11732451 (GC) had a 23% decrease in 25(OH)D after controlling for multiple 
comparisons and covariates. For all Black mothers (EVITA and CPP), there was a significant 
increase in 25(OH)D for rs1844885 and a trend of decreased 25(OH)D for rs10877016 CYP27B1 
SNP. Within EVITA, the meta-analysis observed trends of decreased 25(OH)D (GC: rs962227) 
and increased 25(OH)D (VDR: rs2238135). 
Overall, common SNPs in vitamin D metabolism genes were associated with maternal 
circulating 25(OH)D concentration in pregnancy. To our knowledge, our study is the most 
complete candidate gene analysis of vitamin D in pregnant women to date. Due to the limited 
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literature, our study could not verify previous findings on maternal genetic variations of GC, 
VDR, and CYP27B1 genes and maternal 25(OH)D concentration. 
STRENGTHS AND LIMITATIONS 
Several limitations of this research need to be considered. We had a limited ability to 
conduct meta-analyses within racial/ethnic groups as well as between cohorts due to genotyping 
coverage differences between these groups. Our study had a large number of samples that failed 
quality control steps, therefore we could not adequately compare associations by race/ethnicity. 
Also, our analysis for the gene candidate study on preeclampsia risk was limited to the allelic 
approach due to small sample size and poor genotype quality. We did not have enough power to 
study gene-by-gene interactions. Several common haplotypes affect disease risk; however we did 
not have the statistical power to address this in our analyses. In addition, the relationship 
between SNPs and preeclampsia risk may depend on 25(OH)D status which we could not 
measure. 
Our study could not determine causality between 25(OH)D and preeclampsia risk, as well 
as genetic variation and 25(OH)D concentration. It is possible that the associations we observed 
may be due to shared factors. DBP controls the bioavailability of free 25(OH)D [22], therefore 
DBP levels may be a better predictor of preeclampsia risk, as well as 25(OH)D concentration. 
However, for our genetic studies, we genotyped common SNPs in the GC gene that encodes 
DBP. These SNPs may be serving as a proxy for DBP protein levels. Additionally, there may be 
unmeasured confounders between CPP and EVITA study populations that would reduce our 
ability to compare results; yet by using the meta-analysis approach, we were able to combine 
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results despite this limitation. Our data did not include information on vitamin D supplement use, 
diet, or sun-exposure. Therefore, our results may be biased by unmeasured confounders. Multiple 
measurements of 25(OH)D could have resulted in a better estimate of longer-term exposure and 
reduce the degree of non-differential measurement error; however, our data was limited to one 
measurement. Our genetic analysis may not be generalizable to other racial groups due to 
differences in allelic frequencies by race/ethnicity. Lastly, for our case-cohort, few women had 
25(OH)D <25 nmol/L which led to imprecise estimates. 
Our study has several strengths, including a large sample of racially diverse pregnant 
women consisting of a large number of preeclamptic cases. Our use of two pregnancy cohorts in 
the genetic analysis improved our power for detecting associations when dividing the data by 
race/ethnicity. All of our subjects in the genetic studies were genotyped for ancestral markers, 
therefore we did not rely on self-reported race. Since many variants are ancestral-specific, this 
strategy decreased spurious associations. Circulating 25(OH)D concentrations were measured at 
one laboratory, in as few batches and in as short a time frame as possible, thus attenuating any 
potential technical errors of measurement. In addition, by using tagging SNP approach, we 
reduced redundancy while improving our statistical power for detecting associations. Lastly, we 
used serum samples collected before onset of preeclampsia symptoms, which is important in 
establishing temporality in our first study. 
PUBLIC HEALTH SIGNIFICANCE 
This dissertation makes a significant contribution to public health. Our first paper implies 
low doses of vitamin D supplementation may reduce preeclampsia risk. It also implies that the 
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dose of vitamin D (400IU) in prenatal supplements may be enough to reduce preeclampsia risk. 
Therefore, measures to increase prenatal vitamin D uptake may be more important than 
recommending additional vitamin D supplementation during pregnancy. This is significant since 
the concentration of 25(OH)D to reduce preeclampsia may be the same level recommended by 
the Institute of Medicine to reduce skeletal outcomes. If our findings are supported by 
randomized clinical trials, prenatal supplement uptake may be an important means of preventing 
preeclampsia. 
Due to a dose-response between 25(OH)D and severe and mild preeclampsia, we suggest 
vitamin D deficiency may impact pathophysiologic changes found in both severe and mild 
subtypes of preeclampsia. These changes include an inappropriate inflammatory response, 
endothelial dysfunction, and high blood pressure [237] which may be mediated by VDR and 
vitamin D metabolites [40, 97, 238]. It is possible that common genetic variations in VDR impact 
these pathophysiologic mechanisms and increase a mother’s risk of preeclampsia. 
Our research also observed possible trends of association between several GC and VDR 
SNPs and preeclampsia risk. Despite the poor genotype coverage, one of these GC SNPs 
(rs11732451) was associated with a trend of increased risk of preeclampsia, as well as 
significantly decreased 25(OH)D in Black mothers. If these trends prove to be significant, this 
research will be supporting evidence of a genetic influence in the relationship between 25(OH)D 
and preeclampsia risk. Furthermore, not controlling for this genetic variability between 
individuals may have overestimated the association observed between 25(OH)D and 
preeclampsia risk in EVITA. However, if associations are ancestry-specific, controlling by race 
may have decreased the effect of genetics in EVITA. 
105 
Our study observed common genetic variations in three vitamin D metabolizing genes are 
associated with maternal 25(OH)D. 25(OH)D status in pregnancy is largely dependent on sun 
exposure and diet, but our research observed genetic differences may also be contributing. Due 
to the heritability of 25(OH)D, increasing vitamin D supplements can reduce the environmental 
component of the variability in 25(OH)D between individuals (supplements and season), which 
may expose the inherited inter-individual differences in vitamin D metabolism directed by 
different genotypes. In other words, the rate at which a dose of vitamin D (sunlight or 
supplement) is metabolized may differ by genotype after controlling for confounders, leading to 
different 25(OH)D concentrations by genotype. Therefore, to improve maternal 25(OH)D status 
in pregnancy, vitamin D supplementation may need to consider the influence of genetic variation 
if these findings are confirmed in a replication study. 
FUTURE DIRECTIONS 
Randomized control trials are needed to determine causality between vitamin D deficiency and 
preeclampsia risk. Previous randomized control trials of vitamin D supplements in pregnancy 
may have started supplementation too late in pregnancy to observe an effect on reducing risk of 
preeclampsia [102, 103], and small sample sizes may have reduced power to find a significant 
difference in preeclampsia cases by vitamin D dose. If our research findings are correct, then the 
control dose (400-1000 units/day) may be enough to increase 25(OH)D to 50 nmol/L and reduce 
risk of preeclampsia. Therefore, past randomized control trials may have been limited in power 
to detect a difference in preeclampsia risk by intervention group. 
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As with any other genetic study, replication is needed to confirm results. Since common 
SNPs in these genes have race-specific allelic variations, future work on variation in vitamin D 
metabolism genes and preeclampsia risk should continue to measure associations by 
race/ethnicity. Additionally, the relationship between genetic variation and preeclampsia risk 
may depend on 25(OH)D status. Therefore, additional analyses should test the significance of an 
interaction between vitamin D deficiency and risk allele. Future studies should measure DBP 
levels to provide some insight in the effects of genetic variation in the GC gene on 25(OH)D. 
Other genes are involved in vitamin D metabolism that should be explored in future studies. 
These genes are involved in converting vitamin D to 25(OH)D (CYP2R1), inactivating 25(OH)D 
and 1,25(OH)2D (CYP24A1). 
Assuming these genetic findings are causal, it will be important to find if vitamin D 
supplementation improves 25(OH)D status, as well as reduce their risk of preeclampsia, for those 
with risk variants. To achieve this, the change in 25(OH)D (before and after supplementation) by 
genotype should be assessed to find if rate of vitamin D metabolism differs by genotype. If not, 
then it might not be worthwhile to screen women for genetic factors before supplementation. 
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APPENDIX: TABLES AND FIGURES 
Figure 6. Risk of severe preeclampsia with increasing 25(OH)D concentration (nmol/L) using 
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Figure 7. Risk of mild preeclampsia with increasing 25(OH)D concentration (nmol/L) using 
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